<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-K
(Mark One)
X Annual report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the fiscal year ended March 31, 1998 or
Transition report pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1937
For the transition period from ______ to ______
Commission file number 000-19720
ABAXIS, INC.
(Exact name of registrant as specified in its charter)
California 77-0213001
(State of Incorporation) (I.R.S Employer Identification No.)
1320 Chesapeake Terrace
Sunnyvale, CA 94089
(Address of principal executive offices)
Registrant's telephone number, including area code, is (408) 734-0200
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, No par value
(Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K [ ]
The aggregate market value of the voting stock held by non-affiliates of the
registrant, as of June 22, 1998 was approximately $36,665,533 based upon the
closing sale price reported for such date on the NASDAQ National Market. For
purposes of this disclosure, shares of Common Stock held by persons who hold
more than 5% of the outstanding shares of Common Stock and shares held by
officers and directors of the registrant have been excluded because such persons
may be deemed to be affiliates. This determination of affiliate status is not
necessarily conclusive for other purpose.
The number of shares of the registrant's Common Stock outstanding as of June 22,
1998, was 13,698,806.
<PAGE> 2
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
PART I ......................................................................
ITEM 1. BUSINESS ................................................... 4
General .................................................... 4
In-vitro Diagnostic Testing ................................ 4
Abaxis Products ............................................ 5
Customer Segments and Distribution ......................... 7
Competition ................................................ 9
Manufacturing .............................................. 9
Government Regulation ...................................... 10
Intellectual Property ...................................... 13
Employees .................................................. 14
ITEM 2. PROPERTIES ................................................. 14
ITEM 3. LEGAL PROCEEDINGS .......................................... 15
PART II .....................................................................
ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND
RELATED STOCKHOLDER MATTERS ................................ 15
ITEM 6. SELECTED FINANCIAL DATA .................................... 17
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS .............. 18
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA ....................................................... 23
Report of Deloitte & Touche LLP, Independent Auditors ...... 24
Balance Sheets at March 31, 1998 and 1997 .................. 25
Statements of Operations for the Years Ended March 31, 1998,
1997 and 1996 .............................................. 26
Statements of Shareholders' Equity ......................... 27
Statements of Cash Flows for the Years Ended March 31, 1998,
1997 and 1996 .............................................. 28
Notes to Financial Statements .............................. 29
PART III ....................................................................
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE
REGISTRANT ................................................ 38
</TABLE>
2
<PAGE> 3
TABLE OF CONTENTS
(continued)
<TABLE>
<CAPTION>
Page
----
<S> <C>
ITEM 11. EXECUTIVE COMPENSATION .................................... 41
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT ................................................ 45
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS .............................................. 47
PART IV .....................................................................
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND
REPORTS ON FORM 8-K ....................................... 47
(a) 1. Financial Statements .............................. 47
2. Financial Statements Schedules .................... 47
3. Exhibits .......................................... 47
(b) Reports on Form 8-K .................................. 47
SIGNATURES .................................................................. 48
EXHIBITS INDEX .............................................................. 49
</TABLE>
3
<PAGE> 4
PART I
This report contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934 that reflect the Company's current
view with respect to future events and financial performance. When used in this
report, the words "anticipates", "believes", "expects", "intends", "plans",
"future", and similar expressions identify forward-looking statements. The
future events described in these statements involve risks and uncertainties,
among them risks and uncertainties related to the market acceptance of the
Company's products and continuing development of its products, including
required Food and Drug Administration ("FDA") clearance and other government
approvals, risks associated with manufacturing and distributing its products on
a commercial scale, including complying with Federal and State food and drug
regulations, general market conditions and competition. Actual results could
differ materially from those projected in the forward-looking statements as a
result of factors set forth throughout this document.
ITEM 1. BUSINESS
GENERAL
Abaxis, Inc. (the "Company") develops, manufactures and markets portable blood
analysis systems for use in any patient-care setting to provide clinicians with
rapid blood constituent measurements. The Company's products consist of a
compact 6.9 kilogram analyzer and a series of single-use plastic disks called
reagent discs that contain all the chemicals required to perform a panel of up
to 12 tests. The system can be operated with minimal training and performs
multiple routine tests on whole blood, serum or plasma using either venous or
fingerstick samples. The system provides test results in less than 15 minutes
with the precision and accuracy equivalent to a clinical laboratory analyzer.
The Company currently markets this system for veterinary use under the name
VetScan(R) and in the human medical market under the name Piccolo(R).
The Company offers its point-of-care blood chemistry analyzer system with a
total of 18 test methods. The Company's repertoire of test methods includes
albumin, amylase, alkaline phosphates (ALP), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), direct bilirubin, calcium, creatinine,
creatine kinase (CK), glucose, glutamyl transferase (GGT), potassium, total
bilirubin, total cholesterol, urea nitrogen (BUN), total protein, uric acid, and
thyroxine (T4). Thirteen of these tests are marketed for both human and
veterinary markets, another two tests, uric acid and direct bilirubin, are
marketed only in the human market, and the remaining three tests, CK, T4 and
potassium, are marketed exclusively in the veterinary market. The Company
markets its reagent products by configuring these 18 test methods in panels that
are designed to meet a variety of clinical diagnostic needs. The Company
currently offers seven multi-test reagent disc products in the human medical
market and seven reagent discs in the veterinary market.
Abaxis' focus in fiscal 1999 will continue to be in markets where the Company
believes it can receive immediate economic rewards while at the same time
developing new products that will allow the Company to expand into other market
segments in the following year. Domestically, the Company expects to continue to
focus on growing its presence in the veterinary markets, fulfilling the
Company's contract with the Navy, and expanding its marketing effort to the
other military branches. Internationally, the Company will continue to focus its
sales effort in Europe and Japan as well as explore new markets in Asia and
Latin America.
IN-VITRO DIAGNOSTIC TESTING
More than 20 billion blood tests are performed annually worldwide. These blood
tests are performed mostly in commercial laboratories, hospitals, urgent care
centers or physicians' offices. Sales of in-vitro diagnostic products for use by
these facilities to conduct blood testing total approximately $15 billion per
year. Although over 1,000 different tests are performed on blood, fewer than 50
different tests account for 70% of all blood testing. These tests are considered
the "gatekeepers" of medical care as physicians routinely use them to diagnose
and monitor the treatment
4
<PAGE> 5
of disease. A significant portion of the top 50 tests prescribed by physicians
fall in the clinical chemistry category. In-vitro diagnostic products sold for
the purpose of conducting clinical chemistry tests represent approximately 32%
of the total $15 billion market, while diagnostic testing products for
immunoassay represent another 33% of the market. With such a large volume of
testing, centralized laboratories using automated batch testing equipment have
become the norm in providing physicians the diagnostics test results they need
to make medical treatment decisions.
The current worldwide focus on reducing medical care costs while maintaining
quality of care has encouraged the movement of blood testing out of the central
laboratories into the patient care setting. This trend began in the early 1980s
with the introduction of handheld devices that could perform one or two tests.
In the mid-1980s, small desktop instruments such as the Abbott VISION and the
Kodak DT60 (now marketed by Johnson and Johnson) were introduced for use in
doctors' offices and hospital satellite laboratories. While these systems
allowed testing closer to the patient, they still required skilled technicians
and were limited to performing one test at a time. As a result, multiple tests
could not be performed economically and turnaround time was not significantly
enhanced.
In the United States, there are approximately 40,000 veterinarians who generate
annual billings of approximately $600 million in diagnostic testing. In the
veterinary market blood testing has become more important to veterinarians by
providing them valuable diagnostic information. Veterinarians have historically
relied on the services of the centralized laboratories. The same factors
affecting the human diagnostic market, however, also impact veterinary
practices. Small desk top instruments such as the Dade Behring Analyst, Kodak
DT60, and Idexx VetTest have been marketed to veterinarians to perform in-house
blood testing. While these products have made in-house testing possible for
veterinarians, they still require skilled technicians to properly use and
maintain these products. As a result, based on the Company's market research,
55% of the veterinarians in the United States do not do in-house testing despite
the advantages of in-house testing.
Abaxis believes that a key element of the patient-centered, cost-constrained
health care model in the 1990s and beyond will be the availability of blood
analysis systems in the patient care setting that are easily and reliably
operated by caregivers and provide accurate, real time results for making
immediate clinical decisions. The optimal system uses whole blood, has built-in
calibration and quality control, provides quick turnaround time and is portable
and low in cost. In addition, the optimal near-patient system should be easy to
use by people with no special training and capable of transmitting test results
instantly to a patient information management system.
Abaxis has developed a blood analysis system incorporating all of these criteria
into a 6.5 kilogram analyzer and a series of menu-specific, single-use reagent
discs. The system is essentially a compact portable laboratory that can be
easily carried to the patient. Each reagent disc is pre-configured with multiple
analytes and contains all the reagents necessary to perform a fixed menu of
tests. Taking the system to the patient care site instead of shipping the sample
to a central laboratory makes blood testing and analysis as easy as measuring
the patient's blood pressure, temperature, and heart rate. Additional advantages
of near-patient testing include eliminating errors from sample handling,
transcription, and transportation, which, studies have shown, may cause up to
85% of reporting errors.
ABAXIS PRODUCTS
Point-of-Care Blood Analyzer
The Company's point-of-care blood chemistry analyzer is a portable
spectrophotometer, which is a device that measures the absorption of light at
various wavelengths. A variable speed motor is used to spin the reagent disc for
sample processing. The chemical reactions in the disc's cuvettes are measured
optically by detecting the light absorbance of the solutions in the cuvettes at
pre-determined wavelengths. The absorbances are converted to clinically relevant
units by the measurement microprocessor. Results are stored by the interface
microprocessor, sent to an RS232 port and printed on result cards by an internal
thermal printer. The features of the analyzer include a small required sample
size (100 (mu)L) of whole blood, serum or plasma, an intelligent quality control
system that includes many self-test functions to ensure quality results, a
built-in instrument self calibration, a built-in printer, a quick turn-
5
<PAGE> 6
around time of less than 15 minutes, minimal operational training and ease of
information transmission using a computer port on the analyzer.
Reagent Discs
The reagent discs are designed to handle almost all technical steps of blood
chemistry testing automatically. The discs first separate a whole blood sample
into plasma and blood cells, meter the required quantity of plasma and diluent,
mix the plasma and diluent, and deliver the mixture to the reagent chambers,
called cuvettes, along the disc perimeter. The diluted plasma dissolves and
mixes with the reagent beads initiating the chemical reactions which are
monitored by the analyzer. The discs are 8-cm diameter, single-use devices
constructed from three ultrasonically welded injection-molded plastic parts. The
base and the middle piece create the chambers, cuvettes and passageways for
processing the whole blood and mixing plasma with diluent and reagents. The top
piece, referred to as the bar code ring, is imprinted with bar codes that
contain disc-specific calibration information. In the center of the disc is a
plastic diluent container sealed with polyethylene-laminated foil. Spherical
lyophilized reagent beads are placed in the cuvettes during disc manufacturing.
Upon completion of the analysis, used discs may be placed back into their foil
pouches to minimize human contact with blood prior to proper disposal.
To perform a panel of tests, the operator collects a blood sample via finger
puncture or venipuncture (the latter requiring a trained phlebotomist). The
operator then transfers the sample into the reagent disc. The operator places
the disc into the analyzer drawer, and enters patient, physician, and operator
identification numbers. The analyzer spins the disc to separate cells from
plasma, meters and mixes plasma with diluent, distributes diluted plasma to the
cuvettes, and monitors chemical reactions. In less than 15 minutes, results are
printed out on a result card with an adhesive backing for inclusion in the
patient's medical record. A computer port enables transmission of patient
results to external computers for data management.
The Company introduced its Piccolo system to the human marketplace in November
1995 with two reagent discs, General Health Panel 8 and General Health Panel 11.
In November 1996, the Company introduced the Liver Panel Plus 9 disc, which was
enabled by the 510(k) clearance of the GGT test received from the FDA in
September 1996. Subsequently, the Company has released four other differently
configured reagent disc products to meet different physicians' needs, mostly in
the international markets. As of June 1998, a total of seven reagent disc
products are marketed worldwide for use with the Piccolo system.
The VetScan system was introduced in the US veterinary market in July 1994. The
Company initially launched the system with the Diagnostic Profile, a nine-test
reagent product. Since then, the Company has added new test methods and new
reagent disc products targeted to fulfill different veterinary diagnostic needs.
The newest addition to the VetScan family of reagent products was the Equine
Profile introduced to the market in June 1997. The Equine Profile was optimized
with test methods useful for providing indications of the health condition of
horses, particularly in the areas of hepatic dysfunction and muscle damage. As
of June 1998, the Company offers a total of six reagent disc products to its
veterinary customers.
Orbos Process
The dry reagents used in the Company's reagent discs are produced using a
proprietary technology called the Orbos(R) Discrete Lyophilization Process. This
process allows the production of an accurate, precise amount of active chemical
ingredient in the form of a soluble bead. The Orbos process involves
flash-freezing a drop of liquid reagent to form a solid bead and then
freeze-drying the bead to remove water. The Orbos beads are stable in dry form
and dissolve rapidly in aqueous solutions. The Company believes that the Orbos
process has broad applications in products where delivery of active ingredients
in a stable, pre-metered format is desired. The Company currently has a
licensing agreement with Pharmacia Biotech and a supply contract with Becton
Dickinson Immunocytometry Systems for products produced using the Orbos process.
Abaxis is continuing to explore potential applications with other companies.
There can be no assurance that the Company will be able to discover and/or
develop any new applications for the Orbos process.
6
<PAGE> 7
Future Products
The Company continues to develop new products that the Company believes will
provide further opportunities for market penetration. The Company is working on
development of four electrolyte test methods: total carbon dioxide, chloride,
potassium and sodium. Clinical trials of these test methods have begun and are
expected to be completed during the second quarter of fiscal 1999. Additional
future test methods development for other disc products will be targeted at
specific applications based on fulfilling clinical needs. The Company's current
focus of test methods development is in clinical chemistry. In addition to
clinical chemistry, the Company has demonstrated its ability to perform
immunoassay tests in its blood analysis system by successfully developing its
Thyroxine (T4) test in the veterinary market. The Company believes other
homogeneous immunoassay methods can be performed in its discs to measure a wide
assortment of low concentration blood analytes, such as therapeutic drugs and
drugs of abuse.
There can be no assurance that Abaxis will be able to develop any of these
potential products. While the Company believes that its technology will allow it
to develop reagent disc products in the future to provide a variety of
additional blood tests, there can be no assurance that such future products will
be developed, that such products will receive required regulatory clearance, or
that the Company will be able to manufacture or market such products
successfully.
CUSTOMER SEGMENTS AND DISTRIBUTION
Customer Segments
Abaxis sells its point-of-care blood chemistry analyzer products and reagent
discs either directly or through distributors depending on the needs of the
customer segment. In the delivery of human or veterinary care there are many
kinds of providers and a multitude of sites where Abaxis products could be used
as an alternative to relying on a central laboratory for blood test information.
The Company believes that its current Piccolo system menu of 15 reagent test
methods are suitable for certain niche market segments of the human medical
market. These niche market segments include military installations (ships, field
hospitals and mobile care units), urgent care and walk-in clinics (free-standing
or hospital-connected), home care providers (national, regional or local),
nursing homes, acute care hospitals, ambulance companies, dialysis centers,
hospital labs and draw stations. The Company believes that its veterinary
reagent product offerings meet a substantial part of the clinical diagnostic
needs of veterinarians. Potential customers for the VetScan System are primarily
companion animal hospitals, animal clinics with mixed practices of small
animals, birds and reptiles, equine practitioners, veterinary referral
hospitals, and private toxicology laboratories and university and government
toxicology research laboratories.
Distribution Within North America
Abaxis sells its products directly to those customers who serve large human
patient populations with employed caregivers such as the military, hospitals,
and managed care organizations. As a result of health care reform, the Company
expects a consolidation of providers with more centralized purchasing of medical
products based on the standardization of care and the use of patient outcome
studies to influence purchase decisions. The Company plans to achieve its direct
sales objectives by employing highly skilled sales specialists and eventually
sales teams which will work closely with providers in performing studies to show
that the use of the Piccolo point-of-care blood chemistry analyzer rather than
laboratory alternatives can provide better outcomes at a lower cost.
Abaxis is using distributors for those customers who desire to purchase reagent
discs frequently and in small quantities. These distributors also contribute to
identifying potential customers and introducing the product, but often need the
support of Abaxis personnel in closing the sale. Product distributors are
generally of two types, large companies that primarily serve hospitals, clinics
and large health maintenance organizations (HMOs) nationwide using multiple
warehouses and extensive transportation systems and smaller companies that
provide the daily supplies needed by office-based physicians. In the human
market, national firms sell thousands of products, including furniture, capital
equipment, surgical instruments and a myriad of consumables. The smaller
companies generally
7
<PAGE> 8
direct their product offerings to those items a physician uses daily in caring
for primarily ambulatory patients. These firms also may sell lower priced
equipment such as diagnostic instruments which are used in conjunction with
consumable reagents. The Company currently has non-exclusive distribution
agreements with Allegiance Healthcare Corporation (formerly Baxter Healthcare)
and Sage London of Canada.
Veterinarians are served similarly to office-based physicians by small local
firms, some with national affiliations. The Company currently has a
non-exclusive agreement with VedCo, Inc., a national network of 14 independent
distributors with 23 sales offices in the US. The Company also has five
additional distribution agreements with regional distributors. In addition to
selling through distributors, the Company directly supplies its VetScan products
to two national institutional customers, VCA, the nation's largest veterinary
hospital chain, and VetSmart, the nation's largest chain of veterinary service
clinics. The Company intends to enter into arrangements with additional
distributors as well as pursue direct sales where appropriate. There can be no
assurance that the Company will be successful in securing arrangements with
additional distributors or that any of the Company's distributors will devote
the necessary resources to be successful in their efforts to commercialize the
Company's products.
Distribution Outside of North America
The Company's international sales and marketing objectives include identifying
and defining the market segments in each country by product and then focusing on
specific objectives for each segment in each country. These specific objectives
include modification and expansion of distribution and distributor training and
monitoring to ensure the attainment of sales goals.
The Company currently has exclusive distribution agreements in the following
countries: Argentina, Austria, Brazil, Chile, France, Germany, Greece, Hong
Kong, Italy, Japan, Korea, Mexico, New Zealand, Norway, Portugal, Spain,
Switzerland and the United Kingdom. Each distributor agreement contains a number
of requirements that must be met to retain exclusivity, including minimum order
quantity commitments, trade show and promotion requirements and a specified
number of demonstration analyzer requirements. In most cases, the foreign
distributors need to either go through an FDA-equivalent approval process with
national regulators or clinical trials/market evaluations with their local
opinion leaders in the medical field. Each distributor is responsible for
obtaining the required approvals. There can be no assurance that any of the
Company's distributors will be successful in obtaining proper approvals for
Abaxis products in their respective countries or that these distributors will be
successful in marketing Abaxis products. The Company plans to enter into
additional distribution agreements to enhance its international distribution
base and solidify its international presence. There can be no assurance that the
Company will be successful in entering into any additional distributor
agreements.
Abaxis is party to a series of agreements with Teramecs, the Company's Japanese
distributor, involving funded research, distribution and manufacturing rights
and an equity investment by Teramecs in the Company. Under these agreements
Abaxis has granted Teramecs, subject to certain restrictions, the exclusive
right to distribute Abaxis products in Japan, an option to obtain a license to
manufacture the Piccolo system for resale only to Abaxis or in Japan and access
to future Abaxis technology. Teramecs has provided $1,000,000 of research
funding (which was recognized as revenue by Abaxis in fiscal 1994) and is
obligated to purchase minimum quantities of products annually commencing in June
1996 in order to maintain exclusive distribution rights in Japan. In the event
Teramecs exercises its option to manufacture Abaxis products, it must pay the
Company an additional license fee, purchase from Abaxis the reagent beads for
the products it manufactures, and pay royalties on the sale of such products. In
August 1996, with the regulatory approval from the Japanese Ministry of Health
and Welfare (Koseisho), Teramecs contracted with Daiichi Pure Chemical to
provide more extensive market coverage to sell and distribute the Piccolo system
in the Japanese human medical markets under the name Lunaspin. During fiscal
1998, Teramecs received regulatory approval to market the VetScan system from
the Japanese Ministry of Agriculture, Forestry and Fishery (Nosuisho). There can
be no assurance that Teramecs and Daiichi will be successful in marketing any
Abaxis products.
8
<PAGE> 9
COMPETITION
Abaxis' competition includes clinical laboratories, hospitals and independent
laboratories and manufacturers of bench top multi-test analyzers and other
near-patient test systems. Blood analysis is a well established field in which
there are a number of competitors which have substantially greater financial
resources and larger, more established marketing, sales and service
organizations than the Company. No assurance can be given that the Company's
products will be competitive with existing or future products or services of
such competitors.
Historically, most human medical testing has been performed in the hospital or
commercial laboratory setting. Clinical laboratories have traditionally been
effective at processing large panels of tests using skilled technicians and
complex equipment. The Company's products compete with the clinical laboratories
with respect to range of tests offered, the immediacy of results and cost
effectiveness. While Abaxis cannot provide the same range of tests, the Company
believes that its products will provide a sufficient breadth of test menus to
compete successfully with clinical laboratories on the basis of immediacy of
results and cost effectiveness. The Company's products compete with other
products in the marketplace with respect to ease-of-use, the ability to conduct
tests without a skilled technician, the ability to conduct multiple test panels,
breadth of tests, built-in calibration and quality control, cost effectiveness
and quality of results.
Most of the Company's current and potential competitors have significantly
greater financial and other resources than Abaxis, and the Company expects that
competition will be intense. In particular, most of these competitors have large
sales forces and well-developed channels of distribution. To compete, the
Company must develop effective channels of distribution and a focused direct
sales force. There is no assurance that the Company will be able to compete
successfully.
MANUFACTURING
Abaxis began manufacturing its VetScan products for the commercial market during
fiscal 1995. The Company began manufacturing Piccolo products for commercial
sale in fiscal 1996. To produce and commercially ship Piccolo products, the
Company must have a license to manufacture medical products in the State of
California, where the Company conducts its principal manufacturing activities,
and have approval from the FDA as a medical device manufacturer. In May 1996,
the Company received its license to manufacture from the State of California. In
September 1996, the FDA granted the Company's manufacturing facility "in
compliance" status, according to the regulations for current Good Manufacturing
Practices ("cGMP") for medical devices. The Company is inspected by the FDA and
the State of California on a routine basis, typically once every 24 months.
Although the Company is not required when manufacturing the VetScan products to
comply with all of the government regulations applicable to the human market,
the Company has established all of its manufacturing operations to be cGMP and
Quality System Regulations ("QSR") compliant as this ensures product quality and
integrity regardless of end use or patient. There can be no assurance that the
Company can successfully pass a re-inspection by the FDA or the State of
California or any other future inspections. There can be no assurance that the
Company can comply with all current or future government manufacturing
requirements and regulations.
In addition to the development of standardized manufacturing processes and
quality control programs for the entire manufacturing process, the Company's
manufacturing activities are concentrated in the following three primary areas:
Point-of-Care Blood Chemistry Analyzer
The analyzer used in the Piccolo and VetScan system employs a variety of
components designed or specified by Abaxis, including a variable speed motor,
microprocessors, a liquid crystal display, a result card printer, a
spectrophotometer and other electronic components. These components are
manufactured by several third party vendors that have been qualified and
approved by Abaxis and then assembled by contract manufacturers for Abaxis. The
components are assembled at the Abaxis facility into the finished product and
completely tested to ensure that the finished product meets product
specifications. The analyzer uses technologically advanced components, many of
9
<PAGE> 10
which are available only from single source vendors. During fiscal 1998, the
Company was successful in identifying potential alternate suppliers of some
critical components and will continue to work on qualifying additional vendors
to protect its source of supply on these crucial items. There can be no
assurance that the Company will not experience a material interruption of supply
of components from single source vendors.
Reagent Disc
The molded plastic disks used in the manufacture of the reagent disc are
manufactured to the Company's specification by an established injection-molding
manufacturer. To achieve the precision required for accurate test results, the
disks must be molded to very narrow tolerances. The Company believes only a few
manufacturers are capable of manufacturing to such tolerances. To date, the
Company has qualified one manufacturer to mold the disks and has two molds. The
Company expects to qualify a third production mold by the end of fall 1998 and
has ordered a fourth production mold which it expects to qualify by the end of
fiscal 1999 to better protect its supply source. The Company is also working
with its supplier to improve yields and increase capacity on the existing
production molds. While the Company has increased the number of disk molding
tools to strengthen and better protect its line of supply, the inability of its
injection-molding manufacturer to supply sufficient disks would have a material
adverse impact on the Company's results of operations.
The Company assembles the reagent discs by using the molded plastic disks,
loading the disk with reagents and then ultrasonically welding together the top
and bottom pieces. The Company has begun development of an automated disc
assembly line ("autoline") to provide anticipated capacity for future demand and
to improve production efficiency. The Company expects to have this autoline
fully operational by the end of fiscal 1999. The autoline is expected to double
the Company's capacity while improving quality and yield. The qualification of
the autoline could involve significant time and cost and could entail some
initial unforeseen production problems. There can be no assurance that the
autoline will be fully operational within fiscal 1999, the capacity will be
doubled, quality and yield will improve or that the Company will not experience
significant time requirements and additional cost with the qualification of the
autoline.
Reagent Beads
The reagent discs contain diluent and all the dry reagent chemistry beads
necessary to perform blood analyses. Abaxis purchases chemicals from third party
suppliers and formulates the raw materials, using proprietary processes, into
beads at the proper concentration and consistency to facilitate placement in the
reagent disc and provide homogeneous dissolution and mixing when contacted by
the diluted plasma. The Company is dependent on single source vendors for some
of the chemicals and the loss of any one supplier of chemicals would materially
adversely affect the results of operations. The Company is currently evaluating
additional vendor sources to better protect its lines of supplies in the future.
There can be no assurances that the Company can qualify additional vendor
sources.
GOVERNMENT REGULATION
Piccolo System
Abaxis' Piccolo products are regulated under the 1976 Medical Device Amendments
to the Food, Drug and Cosmetic Act (the "Amendment"). The Company's current
products are Class II devices requiring the submission of a 510(k) FDA
pre-market notification to substantiate label claims prior to marketing. In its
submission, the Company must, among other things, establish that the product to
be marketed is "substantially equivalent" to a product that was on the market
prior to the Amendment or to a product that has previously been cleared under
the 510(k) process. The typical process for clearance of 510(k)'s can be three
months to over a year and the FDA must issue a written order finding substantial
equivalence.
To date, Abaxis has received market clearance for its portable blood analyzer
and 16 test methods from the FDA. Abaxis is currently and plans to continue
developing additional tests that will be required to be cleared through the
10
<PAGE> 11
FDA. There can be no assurance that Abaxis will receive marketing clearance for
any of its future products. The Amendment also requires the Company to
manufacture its products in accordance with the cGMP and QSR using facilities
registered to manufacture the Company's products. The Company's facility is
subject to periodic inspections by the FDA. In addition, the use of the
Company's facilities may be regulated by various state agencies. There can be no
assurance that the Company will be able to maintain facility compliance with
requirements or regulations.
The Piccolo system is also affected by the Clinical Laboratory Improvement
Amendments of 1988 ("CLIA"), which is intended to ensure the quality and
reliability of all medical testing in the United States regardless of where
tests are performed. Under CLIA regulations, laboratory tests are divided into
three categories: "waived or simple", "moderately complex" and "highly complex."
The Company's current products, under these regulations, are classified in the
"moderately complex" category, which would require that any location using these
products be certified as a laboratory. Initial certification would require the
laboratory to obtain a registration certificate from the Health Care Financing
Administration ("HCFA") which would be issued if the laboratory (1) agrees to
notify HCFA within 30 days of any change in its ownership, name or location, (2)
agrees to treat proficiency testing samples in the same manner as patient
specimens and (3) remits the registration fee. Within two years of registration
certificate issuance, laboratories would be inspected to determine compliance
with the CLIA requirements. The CLIA regulations require laboratories to meet
specified standards in the areas of personnel qualification, administration,
participation in proficiency testing, patient test management, quality
control/assurance, laboratory information systems and inspections. There can be
no assurance that CLIA regulations will not have a materially adverse impact on
the Company and its ability to market and sell its products.
In July 1996, the Company filed an application to the Center for Disease Control
("CDC") for its Piccolo system to be waived from the CLIA regulations. If
granted, users of the product can then avoid many of the burdens imposed on
users of moderately complex tests. To have the Piccolo placed in the waived
category, the Company must conduct field studies at three non-laboratory sites
using at least 20 operators each who have no medical laboratory training and can
operate the Piccolo system with directions that require no more than seventh
grade reading skills. The Company met with the CDC in February 1997 to review
its application. The CDC has requested more detailed performance data, which the
Company is in the process of collecting. To date, only a few companies have
received waived category status for their tests and approval time from CDC
appears to be over a year or two. Although the review process for a CLIA waiver
could potentially be very lengthy and costly, the Company believes that its
Piccolo products fulfill all requirements for obtaining a waived status. There
can be no assurance that the Company will be able to obtain a waived status for
its Piccolo system, or that if such waived status was granted, it will enhance
the Company's ability to place Piccolo systems.
Federal and state regulations regarding the manufacture and sale of health care
products and diagnostic devices are subject to future change. The Company cannot
predict what material impact, if any, such changes might have on its business.
In addition, some foreign markets require obtaining foreign regulatory
clearances of the Company's products before they can be distributed in those
countries. There can be no assurance that the Company will be able to obtain
regulatory clearances for its products in the US or in foreign markets.
Although Abaxis believes that it will be able to comply with all applicable
regulations of the FDA and of the State of California, current regulations
depend heavily on administrative interpretations. There can be no assurance that
future interpretations made by the FDA, the HCFA, the CDC or other regulatory
bodies, with possible retroactive effect, will not adversely affect the Company.
Third party payers can indirectly affect the pricing or the relative
attractiveness of the Company's products by regulating the maximum amount of
reimbursement they will provide for blood testing services. For example, the
reimbursement of fees for blood testing services for Medicare beneficiaries is
set by the HCFA. If the reimbursement amounts for blood testing services are
decreased in the future, it may decrease the amount which physicians and
hospitals are able to recover for such services and consequently the price the
Company can charge for its products. If adequate coverage and reimbursement
levels are not provided by government and third-party payers for use of the
Company's products, the market acceptance of those products would be adversely
affected.
11
<PAGE> 12
VetScan System
The government regulations discussed above generally do not apply to the
Company's VetScan products in the US. Internationally, among the countries where
the Company currently has established distribution arrangements, to the
Company's knowledge, Japan is the only market where VetScan products are subject
to government approvals. In Japan, veterinary diagnostic devices are regulated
by the Ministry of Agriculture, Forestry and Fishery, and thus the VetScan
system must be approved by such Ministry prior to being marketed in Japan.
Teramecs, the Company's Japanese distributor, received approval for the VetScan
system at the end of summer 1997.
In order to maintain high quality standards for all its products, the Company is
using the same manufacturing facilities to manufacture all point-of-care blood
chemistry analyzers whether they be for the Piccolo or VetScan system products
and therefore is following the same manufacturing processes and procedures where
practical.
12
<PAGE> 13
INTELLECTUAL PROPERTY
The Company has pursued the development of a patent portfolio to protect its
technology. As of June 22, 1998, the Company has filed 25 United States patent
applications. The following 18 patents have been issued:
<TABLE>
<CAPTION>
Patent No. Description Issue Date
- ---------- ----------- ----------
<S> <C> <C>
5,061,381 Apparatus and Method for Separating Cells from Biological Fluids October 29, 1991
5,122,284 Apparatus and Method for Optically Analyzing Biological Fluids June 16, 1992
5,173,193 Centrifugal Rotor Having Flow Partition December 22, 1992
5,242,606 Sample Metering Port for Analytical Rotor Having Overflow Chamber September 7, 1993
5,275,016 Cryogenic Apparatus January 4, 1994
5,304,348 Reagent Container for Analytical Rotor April 19, 1994
5,403,415 Method and Device for Ultrasonic Welding April 4, 1995
5,409,665 Simultaneous Cuvette Filling with Means to isolate Cuvettes April 25, 1995
5,413,732 Reagent Compositions for Analytical Testing May 9, 1995
5,457,053 Reagent Container for Analytical Rotor October 10, 1995
5,472,603 Analytical Rotor with Dye Mixing Chamber December 5, 1995
5,478,750 Methods for Photometric Analysis December 26, 1995
5,518,930 Simultaneous Cuvette Filling with Means to isolate Cuvettes May 21, 1996
5,590,052 Error Checking in Blood Analyzer December 31, 1996
5,591,643 Simplified Inlet Channels January 7, 1997
5,599,411 Method and Device for Ultrasonic Welding February 4, 1997
5,624,597 Reagent Compositions for Analytical Testing April 29, 1997
5,693,233 Methods of Transporting Fluids within an Analytical Rotor December 2, 1997
</TABLE>
The Company's policy is to file patent applications to protect technology,
inventions and improvements that are important to the development of its
business. The Company also relies upon trade secrets, know-how, continuing
technological innovations and licensing opportunities to develop and maintain
its competitive position. The Company has filed under the Patent Cooperation
Treaty for international patent protection and is selectively filing patents in
countries where the Company expects to market its product.
The patent position of any medical device manufacturer, including Abaxis, is
uncertain and may involve complex legal and factual issues. Consequently, even
though Abaxis is currently executing its patent applications in the US and has
13
<PAGE> 14
filed an international application under the Patent Cooperation Treaty, in
addition to actual foreign patents, the Company does not know whether any of its
applications will result in the issuance of any further patents, or, for any
patents issued, whether they will provide significant proprietary protection or
will be circumvented or invalidated. Since patent applications are maintained in
the US in secrecy until patents issue, and since publications of discoveries in
the scientific or patent literature tend to lag behind actual discoveries by
several months, Abaxis cannot be certain that it was the first creator of
inventions covered by its issued patent or pending patent applications or that
it was the first to file patent applications for such inventions. There can be
no assurance that the Company's patent applications will result in further
patents being issued or that if issued the patents will offer protection against
competitors with similar technology; nor can there be any assurance that others
will not gain patents that the Company would need to license or circumvent.
Moreover, the Company may have to participate in interference proceedings
declared by the US Patent and Trademark Office to determine the priority of
inventions, which could result in substantial cost to the Company.
The Company also relies upon copyright, trademarks and unpatented trade secrets,
and no assurance can be given that others will not independently develop
substantially equivalent proprietary information and techniques or otherwise
gain access to the Company's trade secrets or disclose such technology.
Abaxis requires its employees, consultants and advisors to execute
confidentiality agreements upon the commencement of an employment or consulting
relationship with the Company. Each agreement provides that all confidential
information developed or made known to the individual during the course of the
relationship will be kept confidential and not disclosed to third parties except
in specified circumstances. In the case of employees, the agreements provide
that all inventions conceived by an individual shall be the exclusive property
of the Company, other than inventions unrelated to the Company's business and
developed entirely on the employee's own time. There can be no assurance,
however, that these agreements will provide meaningful protection or adequate
remedies for the Company's trade secrets in the event of unauthorized use or
disclosure of such information.
EMPLOYEES
The Company's success depends upon the continued contribution of its officers
and key personnel, many of whom would be difficult to replace. If certain of
these people were to leave the Company, the Company's ability to achieve its
business objective might be impeded. As of March 31, 1998, the Company had a
total of 76 full-time employees. Twenty employees, including five Ph.D's,
continued to further the Company's research and development activities while
also driving the manufacturing process development. Forty employees worked in
manufacturing operations devoting their time to manufacturing the VetScan and
Piccolo products as well as supporting development activities as necessary. Ten
employees, including one Ph.D, were selling and marketing the VetScan and
Piccolo products. The remaining six employees worked in general administration
to support the Company's administrative requirements. The Company also uses
temporary help to assist in carrying out certain operational duties. As of March
31, 1998, the Company had 18 temporary employees and most of them were assisting
in manufacturing operations. None of the employees are covered by collective
bargaining agreements and management considers its relations with employees to
be good.
ITEM 2. PROPERTIES
The Company occupies approximately 38,300 square feet of office, research and
development and manufacturing space in a building in Sunnyvale, California. The
Company's lease will expire in July 2000. During fiscal 1998 the Company had
adequate space to satisfy all its needs. The Company may need additional space
during fiscal year 1999 for warehousing purposes. Should the need for additional
space arise, the Company believes that suitable additional space will be
available on commercially reasonable terms.
14
<PAGE> 15
ITEM 3. LEGAL PROCEEDINGS
The Company is involved in litigation in the normal course of business. In the
opinion of management, the ultimate resolution of these matters will not have a
material effect on the Company's financial position or results of operations.
PART II
ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED
STOCKHOLDER MATTERS
The Company's initial public offering was completed in January 1992. From that
date, the Company's common stock has been traded on the Nasdaq National Market
under the symbol ABAX.
The high and low prices for the Company's common stock during each quarter since
April 1, 1996 are exhibited in the table below, as represented by the high and
low daily trade closing sales prices as reported by Nasdaq.
<TABLE>
<CAPTION>
Fiscal 1997 High Low
----------- ---- ---
<S> <C> <C>
First Quarter $7.125 $4.125
Second Quarter $6.000 $3.375
Third Quarter $5.750 $2.625
Fourth Quarter $4.250 $2.500
Fiscal 1998
-----------
First Quarter $3.375 $2.625
Second Quarter $5.000 $2.500
Third Quarter $4.000 $2.375
Fourth Quarter $2.875 $1.875
Fiscal 1999
-----------
First Quarter (through June 22, 1998) $3.031 $1.938
</TABLE>
As of June 22, 1998, there were 259 shareholders of record and approximately
4,800 beneficial shareholders. Abaxis has never paid dividends on its common
stock and does not anticipate paying cash dividends in the foreseeable future.
The Company is currently restricted under its Series B Preferred Stock agreement
from paying dividends.
On July 18, 1997, RGC International Investors LDC and Advantage Fund Ltd., each
of which is to the best knowledge of the Company an accredited investor as
defined in Regulation D of the Securities Act of 1933, as amended (the
"Securities Act"), purchased from the Company an aggregate of 3,000 shares of
Series B Convertible Preferred Stock at a price per share of $1,000, with net
proceeds to the Company of approximately $2,768,000. The shares were sold in
this private offering transaction and were not registered under the Securities
Act in reliance upon the exemptions provided by Section 4(2) of the Securities
Act and Regulation D promulgated thereunder as a transaction by an issuer not
involving a public offering. The Series B Preferred Stock is convertible into
the Company's common stock on or before July 18, 2002 at the lesser of $2.7125
or 80% of the average closing bid prices for the five trading days prior to the
conversion date. The Company filed a registration statement on Form S-3 on
September 29, 1997 to register the resale of the common stock issuable upon
conversion of the Series B Preferred Stock. The registration statement was
declared effective on October 30, 1997. During fiscal 1998, 377 shares of the
Series B Preferred Stock were converted into 244,873 shares of common stock. As
of June 22, 1998, 2,650 shares of the Series B Preferred Stock have been
converted into 1,720,736 shares of common stock.
On April 1, 1997, the Company issued 2,824 shares of common stock to a
consultant in payment for investor relations consulting services provided to the
Company during fiscal 1998. These shares were valued at $3.187 per share. On
July 18, 1997, the Company issued 22,120 shares of common stock to a consultant
in payment for services performed
15
<PAGE> 16
in connection with the Corporation's Series B Convertible Preferred Stock
financing during fiscal 1998. These shares were valued at $2.75 per share. The
issuances of common stock were not registered under the Securities Act in
reliance upon the exemptions provided by Section 4(2) of the Securities Act.
16
<PAGE> 17
ITEM 6. SELECTED FINANCIAL DATA
The following selected financial data of the Company are qualified by reference
to and should be read in conjunction with "Management's Discussion and Analysis
of Financial Condition and Results of Operations" and with the consolidated
financial statements, related notes and other financial information included
elsewhere in this report.
<TABLE>
<CAPTION>
------------------------------------------------------------------------------------
STATEMENT OF OPERATIONS DATA: Years Ended March 31,
1998 1997 1996 1995 1994
------------ ------------ ------------ ------------ ------------
<S> <C> <C> <C> <C> <C>
Total revenues $ 12,187,000 $ 7,294,000 $ 2,948,000 $ 1,044,000 $ 1,163,000
------------ ------------ ------------ ------------ ------------
Operating expenses:
Cost of product sales 10,461,000 7,661,000 4,883,000 2,587,000 --
Research and development 1,635,000 1,315,000 1,326,000 4,166,000 8,540,000
Selling, general and administrative 4,741,000 4,867,000 3,482,000 3,504,000 2,175,000
------------ ------------ ------------ ------------ ------------
Total costs and operating expenses 16,837,000 13,843,000 9,691,000 10,257,000 10,715,000
------------ ------------ ------------ ------------ ------------
Loss from operations (4,650,000) (6,549,000) (6,743,000) (9,213,000) (9,552,000)
Interest income and other 370,000 360,000 547,000 376,000 874,000
Interest expense 73,000 -- -- (149,000) (240,000)
------------ ------------ ------------ ------------ ------------
Net loss $ (4,353,000) $ (6,189,000) $ (6,196,000) $ (8,986,000) $ (8,918,000)
============ ============ ============ ============ ============
Basic and diluted loss per share (1) $ (0.44) $ (0.72) $ (0.65) $ (1.24) $ (1.43)
============ ============ ============ ============ ============
Common shares used in computing per
share amounts 11,920,202 10,502,646 9,466,084 7,268,315 6,226,087
============ ============ ============ ============ ============
</TABLE>
<TABLE>
<CAPTION>
---------------------------------------------------------------------------
BALANCE SHEET DATA: March 31,
1998 1997 1996 1995 1994
----------- ----------- ----------- ----------- -----------
<S> <C> <C> <C> <C> <C>
Cash, cash equivalents, and
short-term investments $ 5,897,000 $ 5,321,000 $ 7,778,000 $ 7,195,000 $ 5,573,000
Working capital 5,752,000 6,825,000 7,912,000 7,109,000 3,971,000
Long-term investments -- -- 500,000 700,000 4,500,000
Total assets 12,032,000 11,977,000 13,046,000 12,147,000 13,569,000
Long-term portion of notes payable
and capital lease obligation 263,000 -- -- -- 1,089,000
Total shareholders' equity 7,883,000 9,358,000 10,726,000 10,436,000 10,003,000
</TABLE>
(1) See Note 1 to the Financial Statements for explanation of the loss per share
calculation.
17
<PAGE> 18
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
OVERVIEW
Abaxis, Inc. (the "Company") develops, manufactures and markets portable blood
analysis systems for use in any patient-care setting to provide clinicians with
rapid blood constituent measurements. The Company's products consist of a
compact 6.9 kilogram analyzer and a series of single-use plastic disks called
reagent discs that contain all the chemicals required to perform a panel of up
to 12 tests. The system can be operated with minimal training and performs
multiple routine tests on whole blood, serum or plasma using either venous or
fingerstick samples. The system provides test results in less than 15 minutes
with the precision and accuracy equivalent to a clinical laboratory. The Company
currently markets this system for veterinary use under the name VetScan and in
the human medical market under the name Piccolo.
During the year ended March 31, 1998, the Company achieved record results in
terms of revenues and unit sales, placing 1,086 point-of-care blood chemistry
analyzers worldwide (a 54% increase from fiscal 1997 shipments of 703
point-of-care blood chemistry analyzers), of which 877 were VetScan systems and
209 were Piccolo systems. Reagent discs shipped during fiscal 1998 were
approximately 469,000, an increase of 108% compared to fiscal 1997 shipments of
approximately 225,000 reagent discs. Ninety-four percent (94%) of these reagent
disc shipments were for veterinary applications. The increase in reagent disc
shipments during fiscal 1998 is consistent with the Company's belief that there
will be recurring reagent disc revenue as the Company's product lines mature.
This growth is mostly attributable to the expanded installed base of VetScan
systems and higher consumption rates of institutional users. There can be no
assurance growth in revenues or unit sales will continue or that the Company
will be able to increase production to meet increased product demand.
In fiscal 1998, the Company's US product sales accounted for 67% of its total
revenues, international sales accounted for 30% and Orbos contract revenue
accounted for the remaining 3%. Eighty-one percent (81%) of the sales in the US
were to the veterinary market and 19% were to the human medical market. Sales to
the US Navy and Marines pursuant to a contract awarded in March 1997 totaled 149
Piccolo systems which accounted for essentially all of the human medical market
sales. Through fiscal 1998, the Company has shipped approximately 50% of the
maximum number of analyzers covered by the contract with the US Navy. There can
be no assurances that the US Navy will place purchase orders against the balance
of the contract.
Internationally, sales to Japan constituted 65% and sales to Europe constituted
23% of the total international shipments during fiscal 1998. In July 1997, the
Japanese Ministry of Agriculture, Forestry and Fishery ("Nosuisho") approved
sales of VetScan systems to the approximate 6,000 veterinary practices in Japan.
This approval resulted in the Company placing 327 VetScan systems in Japan
during fiscal 1998. There can be no assurance that the increases in Japanese
sales will continue. The Company also shipped during fiscal 1998 an initial
order of 38 Piccolo systems for use by the Instituto Mexicano del Securo Social
(IMSS). These units were installed in rural clinics throughout Mexico. On June
1, 1998, the Company announced that it had signed an exclusive distribution
agreement with Genzyme Virotech for distribution of the Company's products in
Germany. The agreement included both the VetScan and Piccolo systems. There can
be no assurance that the Company will receive additional orders beyond the terms
of current purchase orders from these and other distributors.
Through March 31, 1998, the Company has placed a total of 2,202 units of its
point-of-care blood chemistry analyzer worldwide, of which 1,741 were VetScan
systems and 461 were Piccolo systems. In North America, the Company has placed
1,189 VetScan systems and 195 Piccolo systems. Internationally (outside of North
America), the Company has placed 552 VetScan systems and 266 Piccolo systems.
Sales for any future periods are not predictable with a significant degree of
certainty. The Company generally operates with limited order backlog because its
products typically are shipped shortly after orders are received. As a result,
product sales in any quarter are generally dependent on orders booked and
shipped in that quarter. The Company's
18
<PAGE> 19
expense levels, which are to a large extent fixed, are based in part on its
expectations as to future revenues. Accordingly the Company may be unable to
adjust spending in a timely manner to compensate for any unexpected revenue
shortfall. As a result, any such shortfall would have an immediate materially
adverse impact on operating results and financial condition. Until sales volume
of the Company's products, particularly its reagent discs, increases
significantly so as to offset associated fixed costs and to realize certain
manufacturing economies of scale, sales of the Company's products will result in
further losses and adversely affect the Company's results of operations and
financial condition. The Company believes that period to period comparisons of
its results of operations are not necessarily meaningful.
The Company's periodic operating results have in the past varied and in the
future may vary significantly depending on, but not limited to, a number of
factors, including the level of competition; the size and timing of sales
orders; market acceptance of current and new products; new product announcements
by the Company or its competitors; changes in pricing by the Company or its
competitors; the ability of the Company to develop, introduce and market new
products on a timely basis; component costs and supply constraints;
manufacturing capacities and ability to scale up production; the mix of product
sales between the analyzers and the reagent discs; mix in sales channels; levels
of expenditure on research and development; changes in Company strategy;
personnel changes; regulatory changes; and general economic trends.
The Company continues to explore the application of its proprietary technology
used to produce the dry reagents used in the reagent discs, called the Orbos
Discrete Lyophilization Process, to other companies' products. This process
allows the production of an accurate, precise amount of active chemical
ingredients in the form of a soluble bead. The Company believes that the Orbos
process has broad applications in products where delivery of active ingredients
in a stable, pre-metered format is desired. The Company has contracts with
Becton Dickinson Immunocytometry Systems and Pharmacia Biotech, Inc. to either
supply products or license Orbos technology. The Company is currently working
with other companies to determine potential suitability of the Orbos technology
to these companies' products. As resources permit, the Company will pursue other
development, licensing or manufacturing agreement opportunities for its Orbos
technology with other companies. There can be no assurances, however, that other
applications will be identified or that additional agreements with the Company
will result.
RESULTS OF OPERATIONS
Revenue
During fiscal 1998, the Company reported total revenues of approximately
$12,187,000, a $4,893,000 or 67% increase from fiscal 1997 total revenues of
approximately $7,294,000. Fiscal 1997 revenue increased $4,346,000 or 147% from
fiscal 1996 total revenues of approximately $2,948,000. Revenue increases in
fiscal 1998 compared to fiscal 1997 was due to increased unit sales of VetScan
systems in the US, sales of Piccolo systems to the US military on a direct basis
without any distributor discounts, which yield higher net revenues, sales of
Piccolo systems to Mexico, increased sales of VetScan systems to the Japanese
market and higher reagent disc sales in the domestic and international markets.
The increase in revenues in fiscal 1997 compared to fiscal 1996 was due to
increased unit sales of point-of-care blood chemistry analyzers, direct sales
during the fourth quarter of fiscal 1997 of Piccolo systems to the US military,
and increased repeat reagent disc sales in both the US and international
markets. Three customers accounted for 29%, 19% and 13%, respectively, of total
revenues for the fiscal year ended March 31, 1998. Three customers accounted for
34%, 20% and 10%, respectively, of total revenues for the fiscal year ended
March 31, 1997. In fiscal year 1996, one customer accounted for 64% of total
revenues.
Cost of Product Sales
Cost of product sales during the year ended March 31, 1998 was approximately
$10,461,000 or 86% of total revenues, as compared to approximately $7,661,000 or
105% of total revenues for the year ended March 31, 1997 and approximately
$4,883,000 or 166% of total revenues for the year ended March 31, 1996. The
increase in cost of product sales for the year ending March 31, 1998 as compared
to the same periods ending March 31,1997 and 1996
19
<PAGE> 20
was primarily a function of the increase in sales volume. The decrease in cost
of product sales as a percentage of total revenues comparing fiscal 1998, 1997
and 1996 is due to lower unit costs resulting from better standardized
manufacturing processes and economies of scale related to increased
manufacturing volume.
Research and Development Expense
The Company incurred research and development expenses of approximately
$1,635,000 in fiscal 1998, compared with approximately $1,315,000 in fiscal 1997
and approximately $1,326,000 in fiscal 1996. The $320,000 or 24% increase in
research and development expenses in fiscal 1998 compared to fiscal 1997 is the
result of increased spending in the development of new test methods offset by
reallocation of a portion of the Company's development resources to support
product manufacturing activities such as manufacturing process development. The
$11,000 or less than 1% decrease in research and development expenses in fiscal
1997 compared to fiscal 1996 is mainly the result of allocation of some of the
Company's development resources to support product manufacturing activities.
Research and development activities accounted for 10% of total operating
expenses during fiscal 1998 as compared to 9% of total operating expenses during
fiscal 1997 and 14% during fiscal 1996. The Company expects the dollar amount of
research and development expenses to increase in fiscal 1999 from fiscal 1998,
as the Company completes development and clinical trials of new test methods to
expand its test menus as well as other development projects. There can be no
assurance, however, that the Company will undertake such research and
development activities in future periods or, if it does, that such activities
will be successful.
Selling, General and Administrative Expense
Selling, general and administrative expenses were approximately $4,741,000 or
39% of total revenues in fiscal 1998, compared to approximately $4,867,000 or
67% of total revenues in fiscal 1997 and approximately $3,482,000 or 118% of
total revenues in fiscal 1996. The decrease in selling, general and
administrative expenses for fiscal 1998 as compared to fiscal 1997 of $126,000
or 3% is primarily the result of certain non-recurring costs associated with the
launch of the Piccolo product line in fiscal 1997 and the Company's cost
containment efforts in fiscal 1998. The increase in expenses in fiscal 1997
compared to fiscal 1996 of $1,385,000 or 40% is related primarily to launching
the Piccolo products worldwide and increases in administrative, sales and
marketing staffing.
Selling, general and administrative expense accounted for approximately 28% of
total operating expenses during fiscal 1998 as compared to 35% of total
operating expenses during fiscal 1997 and 36% of total operating expenses during
fiscal 1996. The Company expects the dollar amount of selling, general and
administrative expense to increase in fiscal 1999 from fiscal 1998, to meet
staffing and support demands associated with increased sales.
Net Interest Income
Net interest income totaled approximately $287,000 or 2% of total revenues for
fiscal 1998, compared to $332,000 or 5% of total revenues in the comparable
period of fiscal 1997. The Company incurred interest expense of approximately
$73,000 on an equipment loan during fiscal 1998. The Company incurred no
interest expense during fiscal 1997. The increase in interest expense was offset
by an increase in interest income of approximately $28,000 during fiscal 1998
compared to interest income during fiscal 1997. This increase in interest income
was primarily the result of increased investment levels.
Interest income totaled $332,000 or 5% of total revenues for fiscal 1997,
compared with $547,000 or 18% of total revenues in fiscal 1996. Interest income
decreased $215,000 or 39% in fiscal 1997 compared to fiscal 1996. The decrease
was primarily the result of decreased investment levels and a lower rate of
return on investments due to shorter terms of the investments. The Company
incurred no interest expense during fiscal 1997 and 1996.
20
<PAGE> 21
Liquidity and Capital Resources
As of March 31, 1998, the Company had approximately $1,701,000 in cash and cash
equivalents and $4,196,000 in short-term investments, for total cash resources
of $5,897,000. The Company expects to incur substantial additional costs to
support its future operations, including further commercialization of its
products and development of new test methods that will allow the Company to
further penetrate the human diagnostic market; acquisition of capital equipment
for the Company's manufacturing facilities, which includes the ongoing costs
related to continuing development of its current and future products;
development and implementation of an automated manufacturing line to provide
capacity for commercial volumes; and additional pre-clinical testing and
clinical trials for its current and future products. The Company is currently
contracting with a vendor to build an automated disc assembly line to provide
additional capacity and to improve production efficiency. The Company estimates
the cost of this new assembly line will be approximately $1,500,000 of which
approximately $992,000 was paid through March 31, 1998. The Company expects to
pay the balance upon acceptance of the equipment which is currently scheduled to
occur during the second quarter of fiscal 1999. During fiscal 1998, in
anticipation of taking delivery of the automated assembly line, the Company
arranged for an equipment financing loan of up to $2,000,000. The equipment
financing loan is collateralized by the Company's equipment and bears interest
at approximately 16%. This loan is due on April 1, 2000. As of March 31, 1998,
the Company has drawn $600,000 against this equipment financing loan of which
$163,000 has been repaid. The Company plans on drawing down the balance of the
loan once the new automated assembly line is delivered to its facility.
Additional manufacturing equipment will also need to be added during fiscal 1999
to provide sufficient production capabilities. Additionally, inventories and
receivables related to increased sales levels of the VetScan and Piccolo systems
could increase significantly in future periods, which would require significant
capital resources.
Net cash used in operating activities during fiscal 1998, was $2,111,000
compared to $6,818,000 net cash used in operating activities during fiscal 1997,
and $5,744,000 net cash used in operating activities fiscal 1996. The decrease
in net cash used in operating activities in fiscal 1998 compared to fiscal 1997
was due to a lower net loss, a decrease in inventories and increases in trade
and other receivables, accounts payable, and accrued payroll and other accrued
liabilities. Net inventories at March 31, 1997, compared to March 31, 1998, were
higher due to preparation for shipment against orders from the Navy and VetSmart
contracts beginning in April 1997. Increases in trade and other receivables and
accounts payable is due to increases in receivable and payable levels associated
with revenue growth. The increase in net cash used in operating activities in
fiscal 1997 compared to fiscal 1996 was the result of increases in trade and
other receivables due to increased revenue in primarily the fourth quarter of
fiscal 1997 from the same period in fiscal 1996, increases in inventory
necessary to meet production demands for increased shipments and a decrease in
trade accounts payable. The increases in net cash used in operating activities
in fiscal 1997 were partially offset by increases in liabilities such as accrued
payroll, other accrued liabilities, warranty reserve and deferred revenue.
Net cash used in investing activities for fiscal 1998 was $870,000 as compared
to $1,842,000 net cash provided by investing activities for fiscal 1997 and
$2,564,000 of net cash used in investing activities in fiscal 1996. The change
from net cash provided by investing activities in fiscal 1997 to net cash used
in investing activities for fiscal 1998 was primarily the result of an increase
in purchases of short-term investments offset by a decrease in the purchase of
property and equipment. The change from net cash used in fiscal 1996 to net cash
provided by investing activities for fiscal 1997 was primarily due to total
maturities of available-for-sale securities exceeding purchases of available-for
sale securities in fiscal 1997 resulting in a decrease of total short-term
investments. Cash provided by maturities and sales of available-for-sale
securities was partially offset by increased purchases of property and equipment
over fiscal 1996 levels.
Net cash provided by financing activities for fiscal 1998 was $3,246,000 as
compared to $4,821,000 net cash provided by financing activities for fiscal 1997
and $6,439,000 of net cash provided by financing activities in fiscal 1996. Cash
provided by financing activities for fiscal 1998 is primarily the result of net
proceeds from issuance of common and preferred stock of $2,809,000 and net
proceeds from equipment financing of $437,000. Cash provided by financing
activities for fiscal 1997 is primarily the result of net proceeds from issuance
of common and preferred stock of
21
<PAGE> 22
$4,847,000. Cash provided by financing activities during this period was
decreased by a $26,000 payment of a preferred stock dividend. Cash provided by
financing activities for fiscal 1996 is the result of proceeds from an offshore
private placement of common stock.
The Company anticipates that its existing capital resources, debt financing and
anticipated revenue from the sales of its products will be adequate to satisfy
its currently planned operating and financial requirements through the next
twelve months. The Company's future capital requirements will largely depend
upon the increased market acceptance of its point-of-care blood chemistry
analyzer products. However, the Company's sales are not predictable due to its
limited market experience with its products. In the event the sales are
significantly below the anticipated level, the Company may need to obtain
additional equity or debt financing. There can be no assurance that any such
financing will be available, and any additional equity financing may be dilutive
to shareholders, while debt financing may involve restrictive covenants.
22
<PAGE> 23
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA
Report of Deloitte & Touche LLP, Independent Auditors
Balance Sheets at March 31, 1998 and 1997
Statements of Operations for Each of the Three Years in the Period Ended
March 31, 1998
Statements of Shareholders' Equity for Each of the Three Years in the
Period Ended March 31, 1998
Statements of Cash Flows for Each of the Three Years in the Period Ended
March 31, 1998
Notes to Financial Statements
23
<PAGE> 24
INDEPENDENT AUDITORS' REPORT
To the Board of Directors and Shareholders of
Abaxis, Inc.:
We have audited the accompanying balance sheets of Abaxis, Inc. (the "Company")
as of March 31, 1998 and 1997 and the related statements of operations,
shareholders' equity, and cash flows for each of the three years in the period
ended March 31, 1998. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, such financial statements present fairly, in all material
respects, the financial position of the Company as of March 31, 1998 and 1997
and the results of its operations and its cash flows for each of the three years
in the period ended March 31, 1998 in conformity with generally accepted
accounting principles.
San Jose, California
April 24, 1998
24
<PAGE> 25
ABAXIS, INC
BALANCE SHEETS
<TABLE>
<CAPTION>
MARCH 31,
-----------------------------------
ASSETS 1998 1997
------------ ------------
<S> <C> <C>
Current assets:
Cash and cash equivalents ................................. $ 1,701,000 $ 1,436,000
Short-term investments .................................... 4,196,000 3,885,000
Trade and other receivables ............................... 1,930,000 1,690,000
Interest receivable ....................................... 130,000 80,000
Inventories ............................................... 1,531,000 2,218,000
Prepaid expenses .......................................... 150,000 135,000
------------ ------------
Total current assets ............................. 9,638,000 9,444,000
Property and equipment - net ................................ 2,309,000 2,453,000
Deposits and other assets ................................... 85,000 80,000
------------ ------------
Total assets ................................................ $ 12,032,000 $ 11,977,000
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable .......................................... $ 1,510,000 $ 695,000
Accrued payroll and related expenses ...................... 769,000 604,000
Other accrued liabilities ................................. 392,000 554,000
Warranty reserve .......................................... 707,000 495,000
Deferred rent ............................................. 68,000 24,000
Current portion of note payable ........................... 174,000 --
Deferred revenue .......................................... 266,000 247,000
------------ ------------
Total current liabilities ........................ 3,886,000 2,619,000
------------ ------------
Note payable ................................................ 263,000 --
------------ ------------
Commitments and contingencies (Note 6)
Shareholders' equity:
Convertible preferred stock, no par value:
authorized shares - 5,000,000; issued
and outstanding shares - 2,623 in 1998 and none in 1997 . 3,179,000 --
Common stock, no par value: authorized shares - 35,000,000;
issued and outstanding shares - 12,187,620 in 1998 and
11,886,153 in 1997 ...................................... 60,362,000 59,783,000
Accumulated deficit ....................................... (55,658,000) (50,425,000)
------------ ------------
Total shareholders' equity ....................... 7,883,000 9,358,000
------------ ------------
Total liabilities and shareholders' equity .................. $ 12,032,000 $ 11,977,000
============ ============
</TABLE>
25
See notes to financial statements
<PAGE> 26
ABAXIS, INC.
STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
YEAR ENDED MARCH 31,
----------------------------------------------------------
1998 1997 1996
------------ ------------ ------------
<S> <C> <C> <C>
Product revenues, net .............................. $ 12,187,000 $ 7,294,000 $ 2,948,000
------------ ------------ ------------
Costs and operating expenses:
Cost of product revenues ......................... 10,461,000 7,661,000 4,883,000
Research and development ......................... 1,635,000 1,315,000 1,326,000
Selling, general and administrative .............. 4,741,000 4,867,000 3,482,000
------------ ------------ ------------
Total costs and operating expenses ................. 16,837,000 13,843,000 9,691,000
------------ ------------ ------------
Loss from operations ............................... (4,650,000) (6,549,000) (6,743,000)
Interest and other income .......................... 370,000 360,000 547,000
Interest expense ................................... (73,000) -- --
------------ ------------ ------------
Net loss ........................................... $ (4,353,000) $ (6,189,000) $ (6,196,000)
============ ============ ============
Basic and diluted loss per share (a) ............... $ (0.44) $ (0.72) $ (0.65)
============ ============ ============
Common stock used in computing basic and diluted per
share amounts ................................... 11,920,202 10,502,646 9,466,084
============ ============ ============
</TABLE>
(a) Loss attributable to common shareholders used in computation of loss per
share for the years ended March 31, 1998 and 1997 was $(5,233,000) and
$(7,595,000), respectively (Note 1).
See notes to financial statements.
26
<PAGE> 27
ABAXIS, INC.
STATEMENTS OF SHAREHOLDERS' EQUITY
<TABLE>
<CAPTION>
CONVERTIBLE PREFERRED STOCK COMMON STOCK
--------------------------- -------------------------- ACCUMULATED
SHARES AMOUNT SHARES AMOUNT DEFICIT
------------ ------------ ------------ ------------ ------------
<S> <C> <C> <C> <C> <C>
Balances at April 1, 1995 ................. -- $ -- 8,719,924 $ 47,117,000 $(36,634,000)
Stock option exercises .................... -- -- 157,704 389,000 --
Issuance of common stock in a private
placement, net of issuance costs
of $23,000 .............................. -- -- 980,000 6,050,000 --
Amortization of deferred compensation ..... -- -- -- -- --
Net loss .................................. -- -- -- -- (6,196,000)
------------ ------------ ------------ ------------ ------------
Balances at March 31, 1996 ................ -- -- 9,857,628 53,556,000 (42,830,000)
Stock option exercises .................... -- -- 20,925 67,000 --
Issuance of Series A preferred stock in a
private placement, net of issuance costs
of $220,000 ............................. 500,000 2,738,000 -- 2,042,000 --
Preferred dividends paid .................. -- -- -- -- (26,000)
Accretion of preferred stock .............. -- 1,380,000 -- -- (1,380,000)
Conversion of Series A preferred stock into
common stock ............................ (500,000) (4,118,000) 2,007,600 4,118,000 --
Net loss .................................. -- -- -- -- (6,189,000)
------------ ------------ ------------ ------------ ------------
Balances at March 31, 1997 ................ -- -- 11,886,153 59,783,000 (50,425,000)
Stock option exercises .................... -- -- 31,650 41,000 --
Issuance of common stock for services ..... -- -- 24,944 69,000 --
Issuance of Series B preferred stock in a
private placement, net of issuance costs
of $232,000 ............................. 3,000 2,018,000 -- 750,000 --
Accretion of preferred stock .............. -- 880,000 -- -- (880,000)
Conversion of Series B preferred stock into
common stock ............................ (377) (469,000) 244,873 469,000 --
Net loss .................................. -- -- -- -- (4,353,000)
------------ ------------ ------------ ------------ ------------
Balances at March 31, 1998 ................ 2,623 $ 2,429,000 12,187,620 $ 61,112,000 $(55,658,000)
============ ============ ============ ============ ============
</TABLE>
<TABLE>
<CAPTION>
TOTAL
DEFERRED SHAREHOLDERS'
COMPENSATION EQUITY
------------ -------------
<S> <C> <C>
Balances at April 1, 1995 ................. $ (47,000) $ 10,436,000
Stock option exercises .................... -- 389,000
Issuance of common stock in a private
placement, net of issuance costs
of $23,000 .............................. -- 6,050,000
Amortization of deferred compensation ..... 47,000 47,000
Net loss .................................. -- (6,196,000)
------------ ------------
Balances at March 31, 1996 ................ -- 10,726,000
Stock option exercises .................... -- 67,000
Issuance of Series A preferred stock in a
private placement, net of issuance costs
of $220,000 ............................. -- 4,780,000
Preferred dividends paid .................. -- (26,000)
Accretion of preferred stock .............. -- --
Conversion of Series A preferred stock into
common stock ............................ -- --
Net loss .................................. -- (6,189,000)
------------ ------------
Balances at March 31, 1997 ................ -- 9,358,000
Stock option exercises .................... -- 41,000
Issuance of common stock for services ..... -- 69,000
Issuance of Series B preferred stock in a
private placement, net of issuance costs
of $232,000 ............................. -- 2,768,000
Accretion of preferred stock .............. -- --
Conversion of Series B preferred stock into
common stock ............................ -- --
Net loss .................................. -- (4,353,000)
------------ ------------
Balances at March 31, 1998 ................ $ -- $ 7,883,000
============ ============
</TABLE>
See notes to financial statements
27
<PAGE> 28
<TABLE>
<CAPTION>
YEAR ENDED MARCH 31,
------------------------------------------
1998 1997 1996
------------ ------------ ------------
<S> <C> <C> <C>
Operating activities:
Net loss ................................................ $ (4,353,000) $ (6,189,000) $ (6,196,000)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation and amortization ......................... 703,000 934,000 657,000
Common stock issued for services ...................... 69,000 -- --
Amortization of deferred compensation ................. -- -- 47,000
Changes in assets and liabilities:
Trade and other receivables ......................... (240,000) (1,000,000) (405,000)
Interest receivable ................................. (50,000) (39,000) (6,000)
Inventories ......................................... 687,000 (762,000) (414,000)
Prepaid expenses .................................... (15,000) (43,000) (19,000)
Deposits and other assets ........................... (5,000) (18,000) (17,000)
Accounts payable .................................... 815,000 (322,000) 519,000
Accrued payroll and related expenses ................ 165,000 187,000 99,000
Other accrued liabilities ........................... 94,000 505,000 (28,000)
Deferred revenue .................................... 19,000 104,000 34,000
Customer deposits ................................... -- (175,000) (15,000)
------------ ------------ ------------
Net cash used in operating activities ............. (2,111,000) (6,818,000) (5,744,000)
------------ ------------ ------------
Investing activities:
Purchase of available-for-sale securities ............... (10,328,000) (27,370,000) (17,194,000)
Maturities of available-for-sale securities ............. 9,526,000 30,172,000 15,250,000
Sales of available-for-sale securities .................. 491,000 -- --
Purchase of property and equipment ...................... (559,000) (960,000) (620,000)
------------ ------------ ------------
Net cash provided by (used in) investing activities (870,000) 1,842,000 (2,564,000)
------------ ------------ ------------
Financing activities:
Proceeds from equipment financing ....................... 600,000 -- --
Repayment of equipment financing ........................ (163,000) -- --
Proceeds from issuance of common and preferred stock .... 2,809,000 4,847,000 6,439,000
Preferred dividends paid ................................ -- (26,000) --
------------ ------------ ------------
Net cash provided by financing activities ......... 3,246,000 4,821,000 6,439,000
------------ ------------ ------------
Net increase (decrease) in cash and cash equivalents ...... 265,000 (155,000) (1,869,000)
Cash and cash equivalents at beginning of year ............ 1,436,000 1,591,000 3,460,000
------------ ------------ ------------
Cash and cash equivalents at end of year .................. $ 1,701,000 $ 1,436,000 $ 1,591,000
============ ============ ============
Supplemental disclosures of cash flow information -
Cash paid for interest .................................. $ 73,000 $ -- $ --
============ ============ ============
Noncash financing activity -
Conversion of preferred stock into common stock ......... $ 469,000 $ 4,118,000 $ --
============ ============ ============
Accretion of preferred stock (Note 8) ................... $ 880,000 $ 1,380,000 $ --
============ ============ ============
</TABLE>
See notes to financial statements.
28
<PAGE> 29
ABAXIS, INC.
NOTES TO FINANCIAL STATEMENTS
YEARS ENDED MARCH 31, 1998, 1997 AND 1996
1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Abaxis, Inc. (the Company) was incorporated in California in 1989 and
develops, manufactures and markets portable blood analysis systems.
FUTURE CAPITAL REQUIREMENTS - The Company expects to incur substantial
costs in fiscal 1999 related to the continued development and marketing
of its products. In addition, future capital requirements will include
amounts necessary to fund accounts receivable, inventories, and capital
equipment acquisitions. The Company believes that its existing capital
resources, available debt facilities and anticipated revenue from VetScan
and Piccolo product sales will be adequate to satisfy its currently
planned financial requirements through fiscal 1999. In the event revenue
is significantly below the anticipated level or there are other
unexpected adverse developments affecting cash flow, the Company will
need to raise additional funds from private or public financing if it is
to sustain its currently planned level of operating expenses during
fiscal 1999, or in the event that the Company is unsuccessful in raising
sufficient funding, the Company will have to significantly reduce its
operating expenses.
CASH EQUIVALENTS AND INVESTMENTS - Cash equivalents consist of short-term
financial instruments with original maturities of less than 90 days from
the date of acquisition that are readily convertible into cash.
Short-term investments have maturities of less than one year from the
balance sheet date and long-term investments have maturities greater than
one year from the balance sheet date.
Investments consist primarily of marketable debt securities that are
classified as "available-for-sale" and are carried at quoted market
prices. Unrealized gains and losses, net of tax, are reportable in
shareholders' equity; however, such amounts have not been material and
therefore were not recorded. The cost basis of investments is adjusted
for the amortization of premiums and the accretion of discounts to
maturity, which is included in interest income. Realized gains and losses
are also included in interest income. The cost of securities sold is
based on the specific identification method.
CONCENTRATION OF CREDIT RISK - Financial instruments that potentially
subject the Company to a concentration of credit risk consist primarily
of cash, cash equivalents, short-term investments, as well as accounts
receivable. The Company has placed the majority of its cash and cash
equivalents and short-term investments in high-credit, high-quality
corporate notes and commercial paper.
The Company sells its products primarily to organizations in the United
States, Japan and Europe. The Company monitors the credit status of its
customers on an ongoing basis and generally does not require its
customers to provide collateral or other security to support accounts
receivable. The Company maintains allowances for potential bad debt
losses. At March 31, 1998, two customers accounted for 39% and 20% of
accounts receivable, respectively. At March 31, 1997, three customers
accounted for 25%, 25% and 15% of accounts receivable, respectively.
PROPERTY AND EQUIPMENT - Property and equipment are stated at cost.
Depreciation and amortization are generally provided using the
straight-line method over the shorter of the estimated useful lives of
the assets (two to five years).
29
<PAGE> 30
INVENTORIES - Inventories are stated at the lower of cost (first-in,
first-out method) or market.
REVENUE RECOGNITION - Revenues are recognized upon shipment. A provision
for the estimated future cost of warranty is made at the time revenue is
recognized.
INCOME TAXES - The Company accounts for income taxes using an asset and
liability approach to recording deferred taxes.
CERTAIN SIGNIFICANT RISKS AND UNCERTAINTIES - The preparation of
financial statements in accordance with generally accepted accounting
principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting
period. Such management estimates include the allowance for doubtful
accounts receivable, the net realizable value of inventory, certain
accruals and warranty reserves. Actual results could differ from those
estimates.
The Company operates in a dynamic industry, and accordingly, can be
affected by a variety of factors. For example, management of the Company
believes that changes in any of the following areas could have a negative
effect on the Company in terms of its future financial position and
results of operations: ability to obtain additional financing; regulatory
changes; uncertainty regarding health care reforms; fundamental changes
in the technology underlying blood testing; the ability to develop new
products that are accepted in the marketplace; competition, including,
but not limited to pricing and products or product features and services;
litigation or other claims against the Company; the adequate and timely
sourcing of inventories; and the hiring, training and retention of key
employees.
PER SHARE INFORMATION - During February 1997, the Financial Accounting
Standards Board issued Statement of Financial Accounting Standards No.
128, "Earnings per Share" (SFAS 128). The Company adopted SFAS 128 in the
third quarter of fiscal 1998 and restated earnings per share (EPS) data
for prior periods to conform with current presentation.
SFAS 128 replaces current EPS reporting requirements and requires a dual
presentation of basic and diluted EPS. Basic EPS excludes dilution and is
computed by dividing net income (loss) by the weighted average number of
common shares outstanding during the period. Diluted EPS reflects the
potential dilution from securities and other contracts which are
exercisable or convertible into common shares.
Diluted EPS is computed by dividing net income (loss) by the weighted
average number of common shares that would have been outstanding during
the period assuming the issuance of common shares for all dilutive
potential common shares outstanding. As a result of operating losses,
there is no difference between the basic and diluted calculations of EPS.
Loss attributable to common shareholders includes the accretion relating
to the calculated imbedded yield representing the discount on the assumed
potential conversion of the preferred stock issued by the Company.
30
<PAGE> 31
The reconciliation of net loss to net loss attributable to common
shareholders is as follows:
<TABLE>
<CAPTION>
YEARS ENDED MARCH 31,
---------------------------------------
1998 1997 1996
----------- ----------- -----------
<S> <C> <C> <C>
Net loss ............................... $(4,353,000) $(6,189,000) $(6,196,000)
Cumulative preferred stock dividends ... -- (26,000) --
Value assigned to accretion of preferred
stock (Note 8) ....................... (880,000) (1,380,000) --
----------- ----------- -----------
Loss attributable to common shareholders $(5,233,000) $(7,595,000) $(6,196,000)
=========== =========== ===========
</TABLE>
STOCK-BASED COMPENSATION - The Company accounts for stock-based awards to
employees using the intrinsic value method in accordance with Accounting
Principles Board Opinion No. 25, "Accounting for Stock Issued to
Employees" (APB No. 25).
RECENTLY ISSUED ACCOUNTING STANDARD - During June 1997, the Financial
Accounting Standards Board issued Statements of Financial Accounting
Standards No. 130, "Reporting Comprehensive Income" (SFAS 130), which
requires that an enterprise report the change in its net assets from
nonowner sources by major components and as a single total. The Board
also issued Statements of Financial Accounting Standards No. 131,
"Disclosures about Segments of an Enterprise and Related Information"
(SFAS 131), which establishes annual and interim reporting standards for
an enterprise's operating segments and related disclosures about its
products, services, geographic areas, and major customers. Adoption of
these statements will not impact the Company's financial position,
results of operations or cash flows, and any effect will be limited to
the form and content of its disclosures. Both statements are effective
for the Company in fiscal 1999.
2. SHORT-TERM INVESTMENTS
At March 31, 1998 and 1997, the amortized cost of "available for sale"
securities approximates the estimated fair value. All investments are in
corporate debt securities with contractual maturities of one year or less
at both March 31, 1998 and 1997.
3. INVENTORIES
Inventories at March 31 consist of the following:
<TABLE>
<CAPTION>
1998 1997
---------- ----------
<S> <C> <C>
Raw materials .......................... $ 909,000 $1,235,000
Work in process ........................ 261,000 723,000
Finished goods ......................... 361,000 260,000
---------- ----------
$1,531,000 $2,218,000
========== ==========
</TABLE>
31
<PAGE> 32
4. PROPERTY AND EQUIPMENT
Property and equipment at March 31 consist of the following:
<TABLE>
<CAPTION>
1998 1997
----------- -----------
<S> <C> <C>
Machinery and equipment ........................ $ 3,867,000 $ 3,412,000
Furniture and fixtures ......................... 922,000 935,000
Computers and computer equipment ............... 879,000 812,000
Leasehold improvements ......................... 312,000 230,000
Construction in progress ....................... 1,224,000 1,367,000
----------- -----------
7,204,000 6,756,000
Accumulated depreciation and amortization ...... (4,895,000) (4,303,000)
----------- -----------
Net property and equipment ..................... $ 2,309,000 $ 2,453,000
=========== ===========
</TABLE>
5. NOTE PAYABLE
The Company maintains a $2,000,000 equipment financing line of credit
which is collateralized by the Company's equipment and bears a 16%
interest rate. As of March 31, 1998, the Company has borrowed $600,000
against the line. Payments are due in monthly installments of principal
and interest of $19,000 with a final balloon payment of $60,000 due on
April 1, 2000. In connection with this equipment financing line, warrants
to purchase 106,667 shares of the Company's common stock at an exercise
price of $3.00 per share were issued to the lender. As of March 31, 1998,
the warrants have not been exercised and will expire on April 30, 2004.
Future payment requirements of the equipment financing line are as
follows:
<TABLE>
<CAPTION>
FISCAL YEAR ENDED
MARCH 31,
<S> <C>
1999 ..................................................... $ 174,000
2000 ..................................................... 204,000
2001 ..................................................... 59,000
---------
$ 437,000
=========
</TABLE>
6. COMMITMENTS AND CONTINGENCIES
LEASES - The Company leases its principal facility under a noncancelable
operating lease agreement that expires in July 2000. Monthly rental
payments increase based on a predetermined schedule. The Company
recognizes rent expense on a straight-line basis over the life of the
lease.
32
<PAGE> 33
The future minimum payments under the operating lease at March 31, 1998
are as follows:
<TABLE>
<CAPTION>
FISCAL YEAR
- -----------
<S> <C>
1999 ......................................................... $ 682,000
2000 ......................................................... 705,000
2001 ......................................................... 237,000
-----------
Total $ 1,624,000
===========
</TABLE>
Rent expense under operating leases was approximately $652,000, $390,000
and $391,000 for the years ended March 31, 1998, 1997 and 1996,
respectively.
LITIGATION - The Company is involved in litigation in the normal course
of business. In the opinion of management, the ultimate resolution of
these matters will not have a material effect on the Company, the
Company's financial position or results of operations.
7. RETIREMENT PLAN
The Company has a tax deferred savings plan for the benefit of qualified
employees. The plan is designed to provide employees with an accumulation
of funds at retirement. Qualified employees may elect to have salary
reduction contributions made to the plan on a quarterly basis. The
Company may make annual contributions to the plan at the discretion of
the Board of Directors. The Company has made no contributions since the
inception of the plan.
8. SHAREHOLDERS' EQUITY
CONVERTIBLE PREFERRED STOCK - In September 1996, the Company sold 500,000
shares of Series A convertible preferred stock in a private placement,
resulting in net proceeds of $4,780,000. The Series A convertible
preferred stock included a conversion feature such that each share was
convertible into common stock at the option of the shareholder based upon
a variable exchange ratio ranging from 71% to 80% of the then current
market price of the Company's common stock, depending upon the timing of
conversion. The imbedded yield to the preferred shareholders as a result
of the discounted conversion feature was allocated to common stock and
was accreted to preferred stock over the preferred stock holding period.
In November and December 1996, the 500,000 shares of Series A convertible
preferred stock were converted into 2,007,600 shares of common stock in
accordance with the specified exchange ratios. In connection with the
conversion, a dividend of $26,000 was paid to the holders of the Series A
preferred stock in accordance with the rights of the shareholders.
During fiscal 1998, the Board of Directors authorized and designated
3,000 shares of Series B convertible preferred stock. In July 1997, the
Company sold the 3,000 shares of Series B convertible preferred stock in
a private placement, resulting in net proceeds of $2,768,000. The Series
B convertible preferred stock includes a conversion feature such that
each share is convertible into common stock at the option of the
shareholder based upon a variable exchange ratio equal to 80% of the
current market price of the Company's common stock, not to exceed 100% of
the average of the closing bid prices for the five consecutive trading
days prior to the Series B convertible preferred stock issuance date. The
Series B convertible preferred stock is also subject to an automatic
conversion into common stock upon the fifth anniversary of the issuance
date. The imbedded yield to the preferred shareholders as a result of the
discounted conversion feature was allocated to common stock and was
accreted to preferred stock over
33
<PAGE> 34
the preferred stock holding period. At March 31, 1998, 377 shares of
Series B preferred stock had been converted to common stock. The Series B
preferred stock does not bear any dividends and the liquidation value of
the preferred shares is equal to the sum of (i) $1,000 plus (ii) an
amount equal to five percent per annum of the Per Share Purchase Price
(the "Accretion Amount") for the period beginning on the issuance date
and ending on the earlier of (i) the date of final distribution to the
holder thereof and (ii) the date that the Accretion Amount stops accruing
pursuant to the Series B Preferred Stock Agreement.
STOCK OPTION PLAN - Under the Company's 1989 Stock Option Plan (the
Option Plan), options to purchase common stock may be granted to
employees and consultants of the Company. Options granted under the
Option Plan may be either incentive stock options or nonqualified stock
options. Incentive stock options are granted at no less than the fair
market value of the common stock on the date of grant, and nonqualified
stock options are granted at no less than 85% of the current fair market
value of the common stock on the date of grant. The stock options
generally expire ten years from the date of grant and normally become
exercisable ratably over four years. Under the Company's Outside
Directors' Stock Option Plan (the Directors' Plan), options to purchase
common stock may be granted only to directors of the Company who are not
employees. Options under the Directors' Plan are nonqualified stock
options and are granted at the fair market value on the date of grant and
expire ten years from the date of grant.
In a prior year, the Company's Board of Directors reserved 20,000 shares
of common stock of which options to purchase 15,000 shares were granted
to a non-employee director at the fair market value of the Company's
common stock on the date of grant. At March 31, 1998, 9,000 of these
options remained outstanding.
34
<PAGE> 35
Information with respect to stock option activity is summarized as
follows:
<TABLE>
<CAPTION>
OPTIONS OUTSTANDING
---------------------------
WEIGHTED
AVERAGE
NUMBER EXERCISE
OF SHARES PRICE
--------- ---------
<S> <C> <C>
Balances at April 1, 1995 (323,778 shares vested at a
weighted average price of $2.22) ..................... 804,874 $3.95
Granted (weighted average fair value of $4.14 per share) 299,000 6.28
Exercised .............................................. (157,704) 2.42
Canceled ............................................... (147,565) 5.20
---------
Balances at March 31, 1996 (368,143 shares vested at a
weighted average price of $3.64) ..................... 798,605 4.85
Granted (weighted average fair value of $2.99 per share) 634,350 4.56
Exercised .............................................. (20,925) 3.23
Canceled ............................................... (234,981) 5.75
---------
Balances at March 31, 1997 (464,065 shares vested at a
weighted average price of $4.15) ..................... 1,177,049 4.54
Granted (weighted average fair value of $1.69 per share) 323,000 2.89
Exercised .............................................. (31,650) 1.28
Canceled ............................................... (301,144) 4.82
---------
Balances at March 31, 1998 ............................. 1,167,255 $4.10
=========
</TABLE>
Additional information regarding options outstanding as of March 31, 1998
is as follows:
<TABLE>
<CAPTION>
OPTIONS OUTSTANDING
---------------------------------------- OPTIONS EXERCISABLE
WEIGHTED ----------------------
AVERAGE WEIGHTED WEIGHTED
REMAINING AVERAGE AVERAGE
RANGE OF NUMBER CONTRACTUAL LIFE EXERCISE NUMBER EXERCISE
EXERCISE PRICES OUTSTANDING (YEARS) PRICE EXERCISABLE PRICE
--------------- ----------- ------- ----- ----------- -----
<S> <C> <C> <C> <C> <C> <C>
$0.32 - $2.25 127,271 4.93 $1.20 87,271 $0.78
$2.50 - $2.52 133,600 9.01 $2.50 26,463 $2.50
$2.53 - $3.13 201,000 9.23 $2.93 36,229 $3.06
$3.19 - $4.63 159,500 6.78 $4.12 123,940 $4.21
$4.69 - $5.00 47,969 6.72 $4.86 34,969 $4.82
$5.13 - $5.13 254,000 8.23 $5.13 111,208 $5.13
$5.25 - $5.75 127,813 7.12 $5.61 90,629 $5.60
$6.00 - $7.75 101,102 6.33 $6.55 85,245 $6.56
$9.11 - $9.11 15,000 2.49 $9.11 9,375 $9.11
--------- -------
$0.32 - $9.11 1,167,255 7.51 $4.10 605,329 $4.39
========= =======
</TABLE>
35
<PAGE> 36
At March 31, 1998, 377,656 and 72,750 shares were available for future
grants under the Option Plan and the Directors' Plan, respectively.
ADDITIONAL STOCK PLAN INFORMATION - As discussed in Note 1, the Company
continues to account for its stock-based awards using the intrinsic value
method in accordance with APB No. 25, and its related interpretations.
Statement of Financial Accounting Standards No. 123, "Accounting for
Stock-Based Compensation" (SFAS 123), requires the disclosure of pro
forma net loss and loss per share had the Company adopted the fair value
method as of the beginning of fiscal 1996. Under SFAS 123, the fair value
of stock-based awards to employees is calculated through the use of
option pricing models, even though such models were developed to estimate
the fair value of freely tradable, fully transferable options without
vesting restrictions, which significantly differ from the Company's stock
option awards. These models also require subjective assumptions,
including future stock price volatility and expected time to exercise,
which greatly affect the calculated values. The Company's calculations
were made using the Black-Scholes option pricing model with the following
weighted average assumptions: expected life, 19 months following vesting;
volatility, 77% in 1998, 91% in 1997 and 92% in 1996; risk-free interest
rates, 5.9% in 1998, 5.8% in 1997 and 4.9% in 1996; and no dividends
during the expected term. The Company's calculations are based on a
multiple option valuation approach, and forfeitures are recognized as
they occur. If the computed fair values of the 1998, 1997 and 1996 awards
had been amortized to expense over the vesting period of the awards, pro
forma net loss would have been $5,055,000 ($0.50 per share) in 1998,
$7,022,000 ($0.80 per share) in 1997 and $6,446,000 ($0.68 per share) in
1996. However, the impact of outstanding non-vested stock options granted
prior to fiscal year 1996 has been excluded from the pro forma
calculation; accordingly, the fiscal years 1998, 1997 and 1996 pro forma
adjustments are not indicative of future period pro forma adjustments,
when the calculation will apply to all applicable stock options.
9. INCOME TAXES
As of March 31, 1998, the Company had federal and state net operating
loss carryforwards of approximately $50,000,000 and $19,000,000,
respectively. The Company also had federal and state research and
development tax credit carryforwards of approximately $1,700,000 and
$860,000, respectively. The net operating loss and credit carryforwards
will expire at various dates from 1999 through 2012, if not utilized. Use
of the Company's net operating loss and tax credit carryforwards may be
limited if a change in ownership, as defined by the Internal Revenue
Code, occurs.
36
<PAGE> 37
Significant components of the Company's deferred tax assets are as
follows:
<TABLE>
<CAPTION>
1998 1997
------------ ------------
<S> <C> <C>
Deferred tax assets:
Net operating loss carryforwards ................. $ 18,000,000 $ 16,500,000
Research and development credit and manufacturer's
investment credit carryforwards ................ 2,560,000 2,400,000
Capitalized research and development ............. 700,000 1,000,000
Other, net ....................................... 570,000 600,000
------------ ------------
Total deferred tax assets........................... 21,830,000 20,500,000
Valuation allowance for deferred tax assets ........ (21,830,000) (20,500,000)
------------ ------------
Net deferred tax assets .......................... $ -- $ --
============ ============
</TABLE>
The Company has not recorded any tax provision or credit for income taxes
due to the Company's historic losses and uncertainties surrounding the
ability to utilize its deferred tax assets in the future.
10. CUSTOMER AND GEOGRAPHIC INFORMATION
Three customers accounted for 29%, 19% and 13%, respectively, of total
revenues for the fiscal year ended March 31, 1998. Three customers
accounted for 34%, 20% and 10%, respectively, of total revenues for the
fiscal year ended March 31, 1997. In fiscal year 1996, one customer
accounted for 64% of total revenues.
The following is a summary of revenues by geographic region:
<TABLE>
<CAPTION>
YEARS ENDED MARCH 31,
-------------------------------------------------
1998 1997 1996
----------- ----------- -----------
<S> <C> <C> <C>
United States ......... $ 8,505,000 $ 4,995,000 $ 2,436,000
Japan ................. 2,301,000 1,452,000 82,000
Europe ................ 730,000 695,000 263,000
Other ................. 651,000 152,000 167,000
----------- ----------- -----------
Total ................. $12,187,000 $ 7,294,000 $ 2,948,000
=========== =========== ===========
</TABLE>
37
<PAGE> 38
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The following table sets forth certain information concerning the directors and
executive officers of the Company as of June 22, 1998.
<TABLE>
<CAPTION>
Name Age Title
- ---------------------------------------- ---------- ----------------------------------------------------
<S> <C> <C>
Clinton H. Severson 50 Chairman of the Board, President, Chief Executive
Officer and Director
Richard Bastiani, Ph.D. (2) 55 Director
Brenton G. A. Hanlon (1) 52 Director
Prithipal Singh, Ph.D. (2) 59 Director
Ernest S. Tucker, III, MD (1) 65 Director
James R. Canfield 39 Vice President of Domestic Marketing and Sales
Robert Milder 48 Vice President of Operations
Diane Oates 44 Vice President of Regulatory Affairs/Quality Systems
Vladimir E. Ostoich, Ph.D. 52 Vice President of Engineering, Founder
Larry Reynolds 49 Vice President of Marketing and Sales,
Pacific Rim and Latin America
Daniel Wong, Ph.D. 46 Vice President of Development
Reba I. Witwer 52 Acting Chief Financial Officer and Controller
</TABLE>
- --------------------------
(1) Member of the Audit Committee
(2) Member of the Compensation Committee
Mr. Severson has served as President, Chief Executive Officer and Director of
the Company since June 1996. He was appointed Chairman of the Board in May 1998.
From February 1989 to May 1996, Mr. Severson served as President and Chief
Executive Officer of MAST Immunosystems, Inc., a medical diagnostic company.
From 1984 to 1989, Mr. Severson was employed by 3M Diagnostic Systems, an
in-vitro allergy test system manufacturer, last serving as General Manager. From
1978 to 1984, Mr. Severson was employed by Syva Company, a medical diagnostic
testing company, in various sales and marketing management positions.
Dr. Bastiani joined the Company's Board of Directors in September 1995. Since
September 1995, Dr. Bastiani has been President of Dendreon, a biotechnology
company. Dr. Bastiani served as President of Syva Company, a medical diagnostic
testing company, from February 1991 until June 1995. From 1971 to February 1991,
Dr. Bastiani held various positions with Syva Company, including Vice President
of Marketing and Sales from 1984 until February 1991.
38
<PAGE> 39
Mr. Hanlon joined the Company's Board of Directors in November 1996. Mr. Hanlon
is President and COO of Tri-Continent Scientific, a subsidiary of Hitachi
Chemical, and a manufacturer of instrumentation for diagnostic applications. Mr.
Hanlon served as Vice President and General Manager of Tri-Continent Scientific
from 1989 to 1996. From 1984 to 1989, Mr. Hanlon was President of Corus Medical,
a medical products company. From 1980 to 1984 he held various marketing
positions with Syva Company, a medical diagnostic company.
Dr. Prithipal Singh joined the Company's Board of Directors in June 1992. Dr.
Singh is a founder of ChemTrak, Inc., a manufacturer of medical diagnostic
equipment, currently serving as Chairman of the Board. From 1985 to August 1988,
Dr. Singh was a Senior Vice President of Idetek, Inc., an animal health care
company. From April 1970 to January 1985, Dr. Singh held a number of positions
with Syva Corporation, now a division of Behring Diagnostics, most recently as a
Vice President.
Dr. Tucker joined the Company's Board of Directors in September 1995. Currently,
Dr. Tucker is Chief Compliance Officer for Scripps Health in San Diego. Dr.
Tucker was Chairman of Pathology at Scripps Clinic and Research Foundation from
1992 to 1997. From 1989 to 1992, Dr. Tucker was Chairman of Pathology at
California Pacific Medical Center. From 1977 to 1988, Dr. Tucker served as the
Director of Immunology Reference Lab of the Research Institute of Scripps
Clinic.
Mr. Canfield joined Abaxis on May 26, 1998 as the Vice President of Domestic
Marketing and Sales. From 1994 to 1998, Mr. Canfield was employed by Idexx
Laboratories, most recently serving as Vice President Marketing and Sales, Idexx
Informatics. From 1990 to 1994, Mr. Canfield was employed by Baxter Healthcare
Corporation, last serving as Regional Vice President, Baxter Distribution. From
1982 to 1989, Mr. Canfield held various sales and marketing positions with
Abbott Diagnostics, a division of Abbott Laboratories.
Mr. Milder joined Abaxis on May 22, 1998 as the Vice President of Operations.
Prior to joining Abaxis, from 1996 to 1998 Mr. Milder was the Vice President of
Manufacturing for Nidek, Inc., a manufacturer of opthalmic and surgical lasers.
From 1992 to 1996, Mr. Milder was Vice President of Operations for Heraeus
Surgical, Inc., a surgical capital equipment manufacturer. Prior to Heraeus, Mr.
Milder was Quality Control Manager for Finnigan MAT Corporation, a manufacturer
of mass spectrometers.
Ms. Oates joined Abaxis in July 1997, as the Director of Regulatory Affairs and
Quality Systems and was promoted to Vice President in April 1998. Prior to
joining Abaxis, from 1990 to 1997, Ms. Oates was Director of Regulatory and
Clinical Affairs for Chiron Diagnostics Corporation, a division of Chiron
Corporation, a biotechnology corporation. From 1987 to 1990, Ms. Oates was
Manager of Regulatory Affairs for California Biotechnology Inc., a manufacturer
of recombinant biopharmaceuticals.
Dr. Ostoich, a co-founder of the Company, has served as Vice President in
various areas of the Company since its inception. Dr. Ostoich first served as
Vice President of Research and Development. Dr. Ostoich has also served as
Senior Vice President of Research and Development, Vice President of Engineering
and Instrument Manufacturing and Vice President of Marketing and Sales for the
United States and Canada. From 1988 to 1989, Dr. Ostoich was employed by Proxim,
Inc., a wireless data communication company, as Vice President of Engineering.
From 1985 to 1987, he was employed as Director of Engineering by Biotrack. From
1980 to 1984, Dr. Ostoich was employed by Hewlett Packard Company in a variety
of engineering positions. From 1972 to 1979, Dr. Ostoich held several faculty
positions at the Technical University of Denmark.
Mr. Reynolds joined Abaxis in February 1997, as the Director of Marketing and
Sales for Pacific Rim and Latin America and was promoted to Vice President in
April 1998. Prior to joining Abaxis, Mr. Reynolds was a managing principal for
LAR Associates, a business planning and development consulting practice. From
1977 to 1996, Mr. Reynolds held various management positions for Behring
Diagnostics Inc., (formerly Syva Company), most recently as Director of New
Business Development.
39
<PAGE> 40
Dr. Wong joined Abaxis in April 1993 as Methods Development Manager and was
named Vice President of Development in May 1994. From January 1995 to February
1996, Mr. Wong also served as Vice President of Development and Reagent
Manufacturing. From 1980 to 1993, Dr. Wong was employed by Miles, Inc. (Bayer),
a medical products company, in a variety of technical and management positions
in its Diagnostics Division.
Ms. Witwer joined Abaxis in September 1996 as Controller and was named Acting
Chief Financial Officer in May 1998. From June 1988 to March 1996, Ms. Witwer
held various management positions, including Corporate Controller, for SSE
Telecom, a telecommunications company.
All directors hold office until the next annual meeting of shareholders of the
Company and until their successors have been elected and qualified. The
Company's Bylaws authorize the Board of Directors to fix the number of directors
at not less than four nor more than seven. The authorized number of directors of
the Company is currently six.
Each officer serves at the discretion of the Board of Directors. There are no
family relationships among any of the directors or officers of the Company.
40
<PAGE> 41
ITEM 11 EXECUTIVE COMPENSATION AND OTHER MATTERS
The following table sets forth information concerning the compensation during
the fiscal years ended March 31, 1998, March 31, 1997 and March 31, 1996 of the
Chief Executive Officer of the Company during fiscal 1998 and four other most
highly compensated executive officers of the Company whose total salary and
bonus for fiscal 1998 exceeded $100,000, for services in all capacities to the
Company, during fiscal 1998.
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG-TERM
FISCAL COMPENSATION
NAME AND PRINCIPAL POSITION YEAR ANNUAL COMPENSATION ($) AWARDS
- ------------------------------------------------- ---------- --------------------------------- --------------
OPTIONS
SALARY BONUS (SHARES)
-------------- ------------ --------------
<S> <C> <C> <C> <C>
CLINTON H. SEVERSON 1998 $193,254 $73,950 50,000
President and Chief Executive Officer 1997 146,535 -0- 250,000
1996 -0- -0- -0-
TING W. LU (1) 1998 116,283 60,550 -0-
Former Vice President of Finance and 1997 120,104 21,700 25,000
Administration, Chief Financial Officer and 1996 116,738 -0- 15,000
Secretary
VLADIMIR E. OSTOICH 1998 139,173 60,550 -0-
Vice President of Marketing and Sales for North 1997 145,287 23,556 25,000
America 1996 142,248 -0- 15,000
LARRY REYNOLDS 1998 86,798 57,980 40,000
Director International Sales and Marketing 1997 -0- -0- -0-
1996 -0- -0- -0-
DANIEL WONG 1998 129,808 60,550 -0-
Vice President of Development 1997 135,296 22,825 25,000
1996 129,815 -0- 15,000
</TABLE>
(1) Ting W. Lu resigned as an employee of the Company in May 1998.
41
<PAGE> 42
STOCK OPTIONS GRANTED IN FISCAL 1998
The following table provides the specified information concerning grants of
options to purchase the Company's Common Stock made during the fiscal year ended
March 31, 1998, to the persons named in the Summary Compensation Table.
OPTION GRANTS IN FISCAL 1998
<TABLE>
<CAPTION>
Potential Realizable
Value at Assumed
Annual Rates of Stock
Price Appreciation for
Individual Grants in Fiscal 1998 Option Term(1)
- ------------------------------------------------------------------------------------------- ---------------------------
Name Options % of Total Exercise Expiration
Granted Options Base Price Date
(#)(2) Granted to ($/Sh) (3)
Employees in 5% ($) 10% ($)
Fiscal Year
- ----------------------- ------------- -------------- ------------ --------------- ------------ ----------
<S> <C> <C> <C> <C> <C> <C>
Clint H. Severson 50,000 15.48 $3.13 4/22/07 $98,265 $249,022
Larry Reynolds 40,000 12.38 3.13 4/22/07 78,612 199,218
</TABLE>
- ---------------------
(1) Potential gains are net of exercise price, but before taxes
associated with exercise. These amounts represent certain assumed
rates of appreciation only, based on the Securities and Exchange
Commission rules. Actual gains, if any, on stock option exercises
are dependent on the future performance of the Common Stock,
overall market conditions and the option holders' continued
employment through the vesting period. The amounts reflected in
this table may not necessarily be achieved.
(2) All options granted in fiscal 1998 were granted pursuant to the
Company's 1989 Stock Option Plan. These options vest and become
exercisable at the rate of one-fourth on the first anniversary of
the date of grant and 1/48 per month thereafter for each full
month of the optionee's continuous employment by the Company.
Under the Company's 1989 Stock Option Plan, the Board retains
discretion to modify the terms, including the price, of
outstanding options. For additional information regarding options,
see "Change of Control Arrangements."
(3) All options were granted at market value on the date of grant.
42
<PAGE> 43
OPTION EXERCISES AND FISCAL 1998 YEAR-END VALUES
The following table provides the specified information concerning exercises of
options to purchase the Company's Common Stock in the fiscal year ended March
31, 1998, and unexercised options held as of March 31, 1998, by the persons
named in the Summary Compensation Table.
OPTION EXERCISES AND FISCAL 1998 YEAR-END VALUES
<TABLE>
<CAPTION>
VALUE OF UNEXERCISED
NUMBER OF UNEXERCISED OPTIONS AT IN-THE-MONEY OPTIONS AT 3/31/98
3/31/98 ($) (2)
---------------------------------- ------------------------------------
SHARES
ACQUIRED VALUE
ON REALIZED
NAME EXERCISE ($) EXERCISABLE(1) UNEXERCISABLE EXERCISABLE (1) UNEXERCISABLE
---- -------- --------- -------------- ------------- --------------- -------------
<S> <C> <C> <C> <C> <C> <C>
Clinton H. Severson -0- -0- 128,125 171,875 $ -0- $ -0-
Ting W. Lu -0- -0- 65,350 15,900 -0- -0-
Vladimir E. Ostoich -0- -0- 90,092 15,533 22,140 -0-
Larry Reynolds -0- -0- 10,833 29,167 -0- -0-
Daniel Wong -0- -0- 69,178 15,822 -0- -0-
</TABLE>
- ------------------------- -------------
(1) Company stock options generally vest one-fourth on the first anniversary
of the date of grant and 1/48 per month thereafter for each full month of
the optionee's continuous employment by the Company. All options are
exercisable only to the extent vested.
(2) The value of the unexercised in-the-money options is based on the closing
price of the Company's Common Stock ($1.938 per share) on March 31, 1998
and is net of the exercise price of such options.
COMPENSATION OF DIRECTORS
All non-employee directors of the Company receive compensation in the amount of
$750 per Board meeting they attend plus reimbursement of reasonable travel
expenses incurred. In addition, Dr. Tucker serves as a consultant to the Company
and receives a monthly compensation of $1,000 plus reimbursement of expenses for
attending meetings at or on behalf of the Company. Each of the Company's
non-employee directors also receives an automatic annual grant of options to
purchase 4,000 shares of Common Stock under the Company's Outside Directors
Stock Option Plan. In addition, Dr. Tucker receives an additional annual grant
of options to purchase 5,000 shares for serving as a consultant. Clinton H.
Severson is a director of the Company and also an employee of the Company. He
does not receive any compensation for his services as a member of the Board of
Directors.
43
<PAGE> 44
CHANGE OF CONTROL ARRANGEMENTS
The Company's 1989 Stock Option Plan and the Outside Directors Stock Option Plan
(the "Option Plans") provide that, in the event of a transfer of control of the
Company ("Transfer of Control"), the surviving, continuing, successor or
purchasing corporation or a parent corporation thereof, as the case may be (the
"Acquiring Corporation"), shall either assume the Company's rights and
obligations under stock option agreements outstanding under the Option Plans
(the "Options") or substitute options for the Acquiring Corporation's stock for
such outstanding Options. In the event the Acquiring Corporation elects not to
assume or substitute for such outstanding Options in connection with a merger
constituting a Transfer of Control, the Company's Board shall provide that any
unexercisable and/or unvested portion of the outstanding Options shall be
immediately exercisable and vested as of a date prior to the Transfer of
Control, as the Company's Board so determines. Any Options which are neither
assumed by the Acquiring Corporation, nor exercised as of the date of the
Transfer of Control, shall terminate effective as of the date of the Transfer of
Control. Options which are assumed by the Acquiring Corporation shall become
exercisable and vested as provided under the relevant stock option agreements
under the Option Plans, unless the Acquiring Corporation terminates the option
holder under certain circumstances defined in the Option Plans. Under such
circumstances, the holder's options shall become immediately exercisable and
vested as of the date of termination.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934 requires the Company's
executive officers, directors and persons who beneficially own more than 10% of
the Company's Common Stock to file initial reports of ownership and reports of
changes in ownership with the Securities and Exchange Commission ("SEC"). Such
persons are required by SEC regulations to furnish the Company with copies of
all Section 16(a) forms filed by such persons.
Based solely on the Company's review of such forms furnished to the Company and
written representations from certain reporting persons, the Company believes
that all filing requirements applicable to the Company's executive officers,
directors and persons who beneficially own more than 10% of the Company's Common
Stock were complied with during fiscal year ended March 31, 1998, with the
following exceptions: Ernest Tucker, Director, filed an Amended Form 3 in
December 1997, reporting a transaction which should have been reported in
September 1995. Ernest Tucker also filed a late Form 4 in December 1997,
reporting a transaction which should have been reported in October 1997. Richard
Bastiani, Director, filed an Amended Form 3 in December 1997, reporting a
transaction which should have been reported in September 1995. Richard Bastiani
also filed a late Form 4 in December 1997, reporting a transaction which should
have been reported in October 1997. Prithipal Singh, Director, filed a late Form
4 in December 1997, reporting a transaction which should have been reported in
October 1997.
CERTAIN TRANSACTIONS
In March 1997, the Company entered into an employment agreement with Clinton H.
Severson, providing Mr. Severson as President and Chief Executive Officer of
Abaxis with six months of salary and benefits if his employment with the Company
is terminated for other than cause.
44
<PAGE> 45
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth as of June 22, 1998, certain information with
respect to the beneficial ownership of the Company's Common Stock by (i) all
persons known by the Company to be the beneficial owners of more than 5% of the
outstanding Common Stock of the Company, (ii) each director and director-nominee
of the Company, (iii) the persons named in the Summary Compensation Table, and
(iv) all executive officers and directors of the Company as a group.
<TABLE>
<CAPTION>
PERCENT OF ABAXIS
NUMBER OF COMMON
SHARES STOCK
OWNED OUTSTANDING(2)
--------- -----------------
<S> <C> <C>
NAME AND ADDRESS OF BENEFICIAL OWNER(1)
Vladimir Ostoich(3) 224,245 1.63%
Clinton H. Severson(4) 209,458 1.51%
Daniel Wong(5) 74,157 *
Ting W. Lu(6) 70,870 *
Ernest S. Tucker, III, M.D.(7) 38,338 *
Prithipal Singh(8) 37,145 *
Richard Bastiani, Ph.D.(9) 16,792 *
Lawrence Reynolds(10) 14,167 *
Brenton G. A. Hanlon(11) 12,667 *
Robert Milder(12) 10,000 *
Executive officers and directors as a group (12 persons)(13) 721,680 5.08%
</TABLE>
* LESS THAN 1%
45
<PAGE> 46
1 The persons named in the table above have sole voting and investment
power with respect to all shares of Common Stock shown as beneficially
owned by them, subject to community property laws where applicable and to
the information contained in the footnotes to this table. Unless
otherwise indicated, the business address of each of the beneficial
owners listed is Abaxis, Inc., 1320 Chesapeake Terrace, Sunnyvale, CA
94089.
2 The percentages shown in this column are calculated from the 13,698,806
shares of Common Stock actually outstanding on June 22, 1998 in addition
to options held by that person that are currently exercisable which are
deemed outstanding in accordance with the rules of the Securities and
Exchange Commission.
3 Includes an aggregate of 29,500 shares held by Dr. Ostoich's IRA, 27,500
shares held by Mrs. Ostoich's IRA and 74,328 shares held of record by the
Vladimir Ostoich and Liliana Ostoich Trust Fund, for the benefit of Dr.
Ostoich and his wife. Also includes 92,917 shares subject to stock
options exercisable by Dr. Ostoich within sixty days of June 22, 1998.
Does not include shares that are held by his adult children as to which
Mr. Ostoich disclaims beneficial ownership.
4 Includes 48,00 shares of stock held by Mr. Severson. Also includes
161,458 shares subject to options exercisable by Mr. Severson within
sixty days of June 22, 1998.
5 Includes 2,000 shares of stock held by Mr. Wong's spouse, as to which Mr.
Wong disclaims beneficial ownership. Also includes 72,157 shares subject
to options exercisable by Dr. Wong within sixty days of June 22, 1998.
6 Includes 4,000 shares of stock held by Ms. Lu. Also includes 66,870
shares subject to options exercisable by Ms. Lu within sixty days of June
22, 1998.
7 Includes 6,545 shares of stock held by Dr. Tucker. Also includes 31,793
shares subject to options exercisable by Dr. Tucker within sixty days of
June 22, 1998.
8 Includes 10,000 shares of stock held by Mr. Singh. Also includes 27,145
shares subject to options exercisable by Mr. Singh within sixty days of
June 22, 1998.
9 Includes 2,000 shares of stock held by Dr. Bastiani. Also includes 14,792
shares subject to options exercisable by Dr. Bastiani within sixty days
of June 22, 1998.
10 Includes 14,167 shares subject to options exercisable by Mr. Reynolds
within sixty days of June 22, 1998.
11 Includes 12,667 shares subject to options exercisable by Mr. Hanlon
within sixty days of June 22, 1998.
12 Includes 10,000 shares of stock held by Mr. Milder.
13 Includes 507,807 shares subject to options exercisable within sixty days
of June 22, 1998.
46
<PAGE> 47
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
None
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
(a) List of documents filed as part of this report:
1. Financial Statements
Reference is made to the Index to Financial Statements under Item 8
of part II hereof, where these documents are included.
2. Financial Statement Schedules
There are no financial statement schedules filed as part of this
report because such schedules are not required to be set forth
therein or the information is shown in the financial statements or
notes thereto.
3. Exhibits filed with this Report on Form 10-K (numbered in
accordance with Item 601 of Regulation S-K)
<TABLE>
<CAPTION>
Exhibit Number Description
<S> <C>
22.1 Subsidiaries of the Registrant
23.1 Consent of Deloitte & Touche LLP, Independent Auditors
27.1 Financial Data Schedule
</TABLE>
(b) Reports on Form 8-K
None
47
<PAGE> 48
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
ABAXIS, INC.
BY /s/ Clinton H. Severson
------------------------------------
Clinton H. Severson
Chairman of the Board, President
and Chief Executive Officer
June 29, 1998
Pursuant to the requirements of the Securities Exchange Act of 1934, this report
has been signed below by the following persons on behalf of the registrant and
in the capacities and on the dates indicated.
<TABLE>
<CAPTION>
Signature Title Date
--------- ----- ----
<S> <C> <C>
/s/ CLINTON H. SEVERSON President, Chief Executive June 29, 1998
- ---------------------------------------- Officer and Director (Principal Executive
Clinton H. Severson Officer)
/s/ REBA I. WITWER Acting Chief Financial Officer and Controller June 29, 1998
- ---------------------------------------- (Principal Financial and Accounting Officer)
Reba I. Witwer
/s/ RICHARD BASTIANI Director June 29, 1998
- ----------------------------------------
Richard Bastiani
/s/ BRENTON G. A. HANLON Director June 29, 1998
- ----------------------------------------
Brenton Hanlon
/s/ PRITHIPAL SINGH Director June 29, 1998
- ----------------------------------------
Prithipal Singh
/s/ ERNEST TUCKER Director June 29, 1998
- ----------------------------------------
Ernest Tucker
</TABLE>
48
<PAGE> 49
EXHIBITS INDEX
<TABLE>
<CAPTION>
Exhibit No. Description of Document
- ----------- -----------------------
<S> <C>
3.1 Restated Articles of Incorporation, as amended (5) (10)
3.2 By-laws of the Company (1)
3.3 Certificate of Determination (12)
10.5 1989 Stock Option Plan as amended and forms of agreement (3)
10.6 1992 Outside Directors Stock Option Plan and forms of agreement (4)
10.7 401(k) Plan (1)
10.8 Lease Agreement between the Company and South Bay/Caribbean dated March
11, 1992 (3)
10.13 Exclusive Distribution Agreement dated September 20, 1991 between the
Company and Teramecs (1) (2)
10.14 Sponsored Research Agreement dated as of September 20, 1991 between the
Company and Teramecs (1) (2)
10.15 Development Agreement between the Company and Becton Dickinson and
Company (through its Becton Dickinson Immunocytometry Systems Division)
dated April 9, 1993 (5) (6)
10.16 Distribution agreement between the Company and VedCo, Inc. dated June 20,
1994 (6)
10.17 Supply Agreement between the Company and Becton Dickinson and Company
(through its Becton Dickinson Immunocytometry Systems Division) dated
September 16, 1994 (6) (7)
10.18 Licensing agreement between the Company and Pharmacia Biotech, Inc. dated
October 1, 1994 (6) (7)
10.19 Employment Agreement with Mr. Gary H. Stroy dated March 11, 1995 (8)
10.20 Employment Agreement with Mr. Clinton H. Severson dated March 31, 1997,
as amended (11)
10.21 Amendment to the Lease Agreement between the Company and South
Bay/Caribbean dated March, 11, 1997 (11)
10.22 Equipment Loan Agreement between the Company and Transamerica Business
Credit dated March 4, 1997 (11)
10.23 Registration Rights Agreement dated July 18, 1997 between the Company and
certain shareholders (12)
10.24 Securities Purchase Agreement dated July 18, 1997 between the Company and
certain shareholders (12)
16.1 Letter from Ernst & Young LLP dated January 30, 1996 (9)
22.1 Subsidiaries of Registrant (Page 51)
23.1 Consent of Deloitte & Touche LLP, Independent Auditors (Page 52)
27.1 Financial Data Schedule
</TABLE>
49
<PAGE> 50
(1) Incorporated by reference from Registration Statement No. 33-44326 filed
December 11, 1991.
(2) Confidential treatment of certain portions of these agreements has been
granted.
(3) Incorporated by reference to the exhibit filed with the Company's Annual
Report on Form 10-K for the fiscal year ended March 31, 1992.
(4) Incorporated by reference to the exhibit filed with the Company's Quarterly
Report on Form 10-Q for the quarter ended September 30, 1992.
(5) Incorporated by reference to the exhibit filed with the Company's Annual
Report on Form 10-K for the fiscal year ended March 31, 1993.
(6) Confidential treatment of certain portions of these agreements has been
granted.
(7) Incorporated by reference to the exhibit filed with the Company's Quarterly
Report on Form 10-Q for the quarter ended September 30, 1994.
(8) Incorporated by reference to the exhibit filed with the Company's Annual
Report on Form 10-K for the fiscal year ended March 31, 1995.
(9) Incorporated by reference to the Company's Report on Form 8-K filed February
1, 1996.
(10) Incorporated by reference to the exhibit filed with the Company's Quarterly
Report on Form 10-Q for the quarter ended December 31, 1996.
(11) Incorporated by reference to the exhibit filed with the Company's Annual
Report on Form 10-K for the fiscal year ended March 31, 1997.
(12) Incorporated by reference to the exhibit filed with the Company's Quarterly
Report on Form 10-Q for the quarter ended June 30, 1997.
50
<PAGE> 1
EXHIBIT 22.1
SUBSIDIARIES OF THE REGISTRANT
None
<PAGE> 1
EXHIBIT 23.1
CONSENT OF DELOITTE & TOUCHE LLP, INDEPENDENT AUDITORS
We consent to the incorporation by reference in Registration Statements Nos.
33-49758, 33-85744 and 333-07541 of Abaxis, Inc. on Form S-8 of our report dated
April 24, 1998, appearing in this Annual Report on Form 10-K of Abaxis, Inc. for
the year ended March 31, 1998.
San Jose, California
June 25, 1998
52
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED STATEMENT OF OPERATIONS AND CONDENSED BALANCE SHEET AND IS QUALIFIED
IN ITS ENTIRETY TO SUCH COMPANY'S YEARLY REPORT ON FORM 10K FOR THE YEAR ENDED
MARCH 31, 1998
</LEGEND>
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> MAR-31-1998
<PERIOD-START> APR-01-1997
<PERIOD-END> MAR-31-1998
<CASH> 1,701,000
<SECURITIES> 4,196,000
<RECEIVABLES> 2,155,000
<ALLOWANCES> (95,000)
<INVENTORY> 1,531,000
<CURRENT-ASSETS> 150,000
<PP&E> 7,204,000
<DEPRECIATION> (4,894,000)
<TOTAL-ASSETS> 12,032,000
<CURRENT-LIABILITIES> 3,886,000
<BONDS> 263,000
0
3,179,000
<COMMON> 60,362,000
<OTHER-SE> (55,658,00)
<TOTAL-LIABILITY-AND-EQUITY> 12,032,000
<SALES> 12,187,000
<TOTAL-REVENUES> 12,187,000
<CGS> 10,461,000
<TOTAL-COSTS> 10,461,000
<OTHER-EXPENSES> 6,376,000
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 73,000
<INCOME-PRETAX> (4,353,000)
<INCOME-TAX> 0
<INCOME-CONTINUING> (4,353,000)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (4,353,000)
<EPS-PRIMARY> (0.44)
<EPS-DILUTED> (0.44)
</TABLE>
